



(A joint stock limited liability company incorporated in the People's Republic of China)
Stock code: 2120



Contents

	/
C , A E I F A I	2
FI A CIA HIGH IGH	4
A AGE E DI C_ I A DA A I	5
C , A E G E A CE A D HE I F A I	31
C IDA ED BA A CE HEE	41
, A E C , A BA A CE HEE	45
C IDA ED I C E A E E	49
, A E C , A I C E A E E	52
C IDA ED CA HF A E E	54
, A E C , A CA HF A E E	57
C IDA ED A E E FCHA GE I HA EH DE 'E _ I	59
, A E C , A A E E FCHA GE I HA EH DE 'E _ I	61
E HEFI A CIA A E E	63
DEFI I I	151



Corporate Information

Board of Directors

Executive Directors

Mr. Gao A (Chairman) 1
 Mr. A G 1
 Mr. A G Jr 1

Non-executive Directors

Mr. I H 1
 Mr. I C 1

Independent Non-executive Directors

Mr. H G 1
 Mr. JI 1
 Mr. CHA 1 H

Supervisory Board

Mr. H G (Chairman) 1
 Mr. I C 1
 Mr. JI 1

Management

Mr. CHA 1 H (Chairman) 1
 Mr. Gao A 1
 Mr. JI 1

Senior Management

Mr. JI 1 (Chairman) 1
 Mr. H G 1
 Mr. CHA 1 H

Shareholders

Mr. Gao A (Chairman) 1
 Mr. H G 1
 Mr. I H 1

Shareholders

Mr. - 1 (Chairman) 1
 Mr. - 1
 Mr. HA G 1
 Mr. IE 1
 Mr. IA C 1

Shareholders

Mr. A G Jr 1
 Mr. G 1 C 1

Shareholders

Mr. Gao A 1
 Mr. G 1 C 1

Shareholders

BD C 1 C 1 A 1

Shareholders

C 1 C

Shareholders

H 1 D 1
 H 1 D 1
 C 1

Corporate Information

Wenzhou Kangning Hospital Co., Ltd. B

40/F, D F C
248 E

H

H

C H I 1712-1716, 17 F

H C
183 E

H

C

2120

C

I

: (86) 577 8877 1689

F : (86) 577 8878 9117

E : .

Financial Highlights

For the six months ended June 30, 2024

	For the six months ended June 30, 2024 (RMB' 000) (Unaudited)	2023 (B'000) (- ● 1 ●)
Revenue	828,957	777,925
Cost of services	61,513	60,207
Medical materials	16,516	11,478
Other materials	44,996	48,729
Medical equipment	50,724	43,750
Medical waste disposal	-5,727	4,979
Other operating expenses	116,536	113,591

	As at June 30, 2024 (RMB' 000) (Unaudited)	A 31, 2023 (B'000) (A ● 1 ●)
Assets	3,008,352	3,047,687
Liabilities	1,581,890	1,639,481
Equity	1,426,462	1,408,206
Medical equipment	1,290,906	1,265,065
Medical waste disposal	135,555	143,141

Management Discussion and Analysis

B. I E E IE A D

I 2024, ... G ... C ... F ... G ...

I 2024, G ... B829.0 ... 6.6% ... B765.6 ... 5.1% ... D ... B50.7 ... 15.9% ... A J 30, 2024, ... 32 (D 31, 2023: 32), ... 11,648 (D 31, 2023: 11,268).

Psychiatric Healthcare Business

G ... G ...

Management Discussion and Analysis

[illegible]

Elderly Healthcare Business

A 2016. G
2016. G
J 15, 2024, C G
C D E I E (G 72024 . 1)
《辦公廳關於發展銀髮經濟增進老年人福祉的意見》(國辦發〔2024 1號)), 26 A
J 18, 2024, C C
C C C E
D C A C 《中共中央關於進一步全面深化改革推進中國式
現代化的決定》),
A

Management Discussion and Analysis

I 2024, G 2,730, B238.1 31.1% G A G H C H 2022, C G H 2022, H C 2021,

I J 2024, G C D 2024 《深化醫藥衛生體制改革2024年重點工作任務》, (固本革新,篤信行遠), H G

Management Discussion and Analysis

F₁ 1 1

G B829.0 6.6%
 2023. A 5.1% 2023. D
 B765.6 27.5% 30,
 2023: 24.9%). G B226.2 12.2%
 2023. D
 C B50.7 15.9%
 2023. D B116.5 30, 2023: B113.6 2.6%
 2023.

Revenue and Cost of Revenue

G : () ; ()
 () ()
 : :

For the six months ended June 30,

	2024	2023
	(RMB' 000)	(B'000)
	(Unaudited)	(- . 1 .)
	765,636	728,692
	63,023	46,375
	298	2,858
Total revenue	828,957	777,925

Management Discussion and Analysis

● 2024 年 1-6 月，公司实现营业收入 765,636 千元，较 2023 年 1-6 月增加 2.1%。其中，医疗服务收入 744,197 千元，较 2023 年 1-6 月增加 1.3%；药品收入 19,256 千元，较 2023 年 1-6 月增加 18.5%。营业收入的构成情况如下表所示：

	(Billing Revenue)
营业收入	765,636
其中：	
医疗服务收入	744,197
药品收入	19,256

	For the six months ended June 30,	
	2024	2023
	(RMB' 000)	(B'000)
	(Unaudited)	(- ● ●)
营业收入	765,636	728,692
其中：		
医疗服务收入	744,197	719,197
药品收入	19,256	15,505

● 2024 年 1-6 月，公司营业成本 19,256 千元，较 2023 年 1-6 月增加 18.5%。其中，药品成本 15,505 千元，较 2023 年 1-6 月增加 18.5%；医疗服务成本 3,751 千元，较 2023 年 1-6 月增加 1.3%。营业成本的构成情况如下表所示：

	(Cost)
营业成本	19,256
其中：	
药品成本	15,505
医疗服务成本	3,751

● 2024 年 1-6 月，公司毛利率为 74.5%，较 2023 年 1-6 月提高 0.5 个百分点。其中，药品毛利率为 18.5%，较 2023 年 1-6 月提高 0.5 个百分点；医疗服务毛利率为 74.5%，较 2023 年 1-6 月提高 0.5 个百分点。

Management Discussion and Analysis

	For the six months ended June 30, 2024 (RMB' 000) (Unaudited)	2023 (B'000) (- 1 1)
Billing Revenue from owned hospitals	784,892	744,197
C	555,218	547,492
G	229,674	196,705

[illegible]

	For the six months ended June 30, 2024 (Unaudited)	2023 (- 000)
Inpatients		
Inpatient days	11,648	10,578
Estimated inpatient revenue	2,119,936	1,914,618
- inpatient revenue (%)	87.4	84.0
Estimated inpatient revenue	1,852,397	1,607,422
Estimated inpatient revenue (B'000)	586,146	553,572
Estimated inpatient revenue (B)	317	345
Estimated inpatient revenue (B'000)	91,056	84,197
Estimated inpatient revenue (B)	49	52
Total inpatient revenue (RMB'000)	677,202	637,769
Total average inpatient spending per bed-day (RMB)	366	397
Outpatients		
Outpatient visits	243,108	250,648
Estimated outpatient revenue	31,560	33,647
Estimated outpatient revenue (B)	130	134
Estimated outpatient revenue (B'000)	76,130	72,781
Estimated outpatient revenue (B)	313	291
Total outpatient revenue (RMB'000)	107,690	106,428
Total average outpatient spending per visit (RMB)	443	425
Total treatment and general healthcare services revenue (RMB'000)	617,706	587,219
Total pharmaceutical sales revenue (RMB'000)	167,186	156,978

Management Discussion and Analysis

During the six months ended June 30, 2024, the Company's total revenue was RMB677.2 million, an increase of 6.2% compared with RMB637.2 million for the same period in 2023. The increase was primarily due to the increase in the revenue of the Company's owned hospitals, which was 15.2% compared with the same period in 2023. The revenue of the Company's owned hospitals was RMB607.7 million, an increase of 15.2% compared with RMB527.7 million for the same period in 2023. The revenue of the Company's owned hospitals was primarily derived from the revenue of the Company's owned hospitals, which was 86.3% compared with 85.7% for the same period in 2023.

During the six months ended June 30, 2024, the Company's total revenue was RMB107.7 million, an increase of 1.2% compared with RMB106.5 million for the same period in 2023. The increase was primarily due to the increase in the revenue of the Company's owned hospitals, which was 4.2% compared with the same period in 2023. The revenue of the Company's owned hospitals was RMB107.7 million, an increase of 4.2% compared with RMB103.5 million for the same period in 2023. The revenue of the Company's owned hospitals was primarily derived from the revenue of the Company's owned hospitals, which was 13.7% compared with 14.3% for the same period in 2023.

During the six months ended June 30, 2024, the Company's total revenue was RMB5.2 million, an increase of 5.2% compared with RMB4.9 million for the same period in 2023. The increase was primarily due to the increase in the revenue of the Company's owned hospitals, which was 78.7% compared with the same period in 2023. The revenue of the Company's owned hospitals was RMB5.2 million, an increase of 78.7% compared with RMB4.9 million for the same period in 2023. The revenue of the Company's owned hospitals was primarily derived from the revenue of the Company's owned hospitals, which was 78.7% compared with 78.9% for the same period in 2023. The revenue of the Company's owned hospitals was RMB5.2 million, an increase of 6.5% compared with RMB4.9 million for the same period in 2023. The revenue of the Company's owned hospitals was primarily derived from the revenue of the Company's owned hospitals, which was 21.3% compared with 21.1% for the same period in 2023. The revenue of the Company's owned hospitals was RMB5.2 million, an increase of 13.4% compared with RMB4.9 million for the same period in 2023. The revenue of the Company's owned hospitals was primarily derived from the revenue of the Company's owned hospitals, which was 70.7% compared with 68.4% for the same period in 2023.

C

	For the six months ended June 30, 2024 (RMB'000) (Unaudited)	2023 (RMB'000) (Unaudited)
Revenue of owned hospitals	177,398	188,867
Revenue of non-owned hospitals	228,188	208,780
Revenue of other hospitals	14,557	17,993
Revenue of other hospitals	52,308	49,033
Revenue of other hospitals	33,351	32,373
Revenue of other hospitals	8,450	10,630
Revenue of other hospitals	40,966	39,816
Cost of revenue of owned hospitals	555,218	547,492

Management Discussion and Analysis

D 1. 1.4% 2023. 9.3% 6.1% 0.2% 2023.

F 32.0% (J 30, 2023: 34.5%). 41.1% (J 30, 2023: 38.1%). 12.0% (J 30, 2023: 12.2%).

G B63.0 B41.7 (J 30, 2023: B29.1).

G B0.3 (J 30, 2023: B2.9), H

Management Discussion and Analysis

Gross Profit and Gross Profit Margin

During the six months ended June 30, 2024, the Company's gross profit was RMB226.2 million, an increase of 12.2% compared with the gross profit of RMB210.4 million for the same period in 2023. The gross profit margin was 27.3%, an increase of 1.4 percentage points from 25.9% in 2023. The increase in gross profit and gross profit margin was mainly due to the increase in the number of inpatients and the improvement of the medical service quality.

	For the six months ended June 30,	
	2024	2023
	(Unaudited)	(Audited)
Gross profit	27.5%	24.9%
Gross profit margin	24.9%	41.3%
Consolidated gross profit margin	27.3%	25.9%

During the six months ended June 30, 2024, the Company's gross profit was RMB226.2 million, an increase of 12.2% compared with the gross profit of RMB210.4 million for the same period in 2023. The gross profit margin was 27.3%, an increase of 1.4 percentage points from 25.9% in 2023. The increase in gross profit and gross profit margin was mainly due to the increase in the number of inpatients and the improvement of the medical service quality.

Tax and Surcharge

During the six months ended June 30, 2024, the Company's tax and surcharge was RMB6.3 million, an increase of 2.6 percentage points from RMB2.8 million for the same period in 2023.

Selling Expenses

During the six months ended June 30, 2024, the Company's selling expenses were RMB9.2 million, an increase of 1.2 percentage points from RMB7.8 million for the same period in 2023. The increase in selling expenses was mainly due to the increase in the number of inpatients and the improvement of the medical service quality.

Management Discussion and Analysis

Administrative Expenses

During the six months ended June 30, 2024, administrative expenses increased by 4.3% compared with the same period in 2023. The increase was mainly due to the increase in depreciation and amortization expenses, which increased by 15.1% compared with the same period in 2023. The increase in depreciation and amortization expenses was mainly due to the increase in the depreciation and amortization of fixed assets and intangible assets. The increase in depreciation and amortization expenses was mainly due to the increase in the depreciation and amortization of fixed assets and intangible assets.	For the six months ended June 30,	
	2024 (RMB'000) (Unaudited)	2023 (B'000) (- 0.00)
Depreciation and amortization	64,383	55,922
Salaries and wages	13,955	13,474
Office rent	4,042	14,377
Utilities	2,199	2,071
Other administrative expenses	21,692	16,080
Total administrative expenses	106,271	101,924

During the six months ended June 30, 2024, administrative expenses increased by 4.3% compared with the same period in 2023. The increase was mainly due to the increase in depreciation and amortization expenses, which increased by 15.1% compared with the same period in 2023. The increase in depreciation and amortization expenses was mainly due to the increase in the depreciation and amortization of fixed assets and intangible assets. The increase in depreciation and amortization expenses was mainly due to the increase in the depreciation and amortization of fixed assets and intangible assets.

During the six months ended June 30, 2024, administrative expenses increased by 4.3% compared with the same period in 2023. The increase was mainly due to the increase in depreciation and amortization expenses, which increased by 15.1% compared with the same period in 2023. The increase in depreciation and amortization expenses was mainly due to the increase in the depreciation and amortization of fixed assets and intangible assets. The increase in depreciation and amortization expenses was mainly due to the increase in the depreciation and amortization of fixed assets and intangible assets.

During the six months ended June 30, 2024, administrative expenses increased by 4.3% compared with the same period in 2023. The increase was mainly due to the increase in depreciation and amortization expenses, which increased by 15.1% compared with the same period in 2023. The increase in depreciation and amortization expenses was mainly due to the increase in the depreciation and amortization of fixed assets and intangible assets. The increase in depreciation and amortization expenses was mainly due to the increase in the depreciation and amortization of fixed assets and intangible assets.

Management Discussion and Analysis

Research and Development Expenses

During the six months ended June 30, 2024, the Company's research and development expenses were RMB12,779,000, an increase of 17.6% compared with RMB9,691,000 for the same period in 2023. The increase was mainly due to the increase in research and development expenses for the Company's main products, including the development of new products and the improvement of existing products.

	For the six months ended June 30,	
	2024	2023
	(RMB'000)	(RMB'000)
	(Unaudited)	(Unaudited)
Research and development expenses	12,779	9,691
Research and development expenses for the Company's main products	4,035	3,259
Research and development expenses for the Company's other products	748	1,982
Research and development expenses for the Company's other products	26	26
Total	17,588	14,958

During the six months ended June 30, 2024, the Company's research and development expenses for the Company's main products were RMB4,035,000, an increase of 17.6% compared with RMB3,259,000 for the same period in 2023. The increase was mainly due to the increase in research and development expenses for the Company's main products, including the development of new products and the improvement of existing products.

Management Discussion and Analysis

Finance Expenses – Net

For the six months ended June 30,		
	2024	2023
	(RMB' 000)	(B'000)
	(Unaudited)	(- ● □ ●)
Interest expense	-2,686	-2,705
Exchange loss	99	-13
Bank charges	18,078	14,124
Interest income	5,245	5,058
Net finance expenses	2,968	3,151
	761	545
Finance expenses – net	24,465	20,160

During the six months ended June 30, 2024, the net finance expenses were RMB24,465,000 (unaudited), compared with RMB20,160,000 for the same period in 2023. The increase was mainly due to the increase in bank charges from RMB14,124,000 in 2023 to RMB18,078,000 in 2024.

Management Discussion and Analysis

Investment Income/Loss

During the six months ended June 30, 2024, the Company's investment income was RMB 479,000 (unaudited), compared with a loss of RMB 158,000 (unaudited) for the same period in 2023. The increase in investment income was primarily due to the disposal of certain investment properties during the period.

	For the six months ended June 30,	
	2024	2023
	(RMB'000)	(B'000)
	(Unaudited)	(- ● ●)
Investment income	479	-158
Gain on disposal of investment properties	1,201	-38
	1,680	-196

During the six months ended June 30, 2024, the Company's credit impairment losses were RMB 1,680,000 (unaudited), compared with RMB 196,000 (unaudited) for the same period in 2023. The increase in credit impairment losses was primarily due to the increase in the number of patients and the corresponding increase in the Company's credit exposure.

Credit Impairment Losses

During the six months ended June 30, 2024, the Company's credit impairment losses were RMB 1,680,000 (unaudited), compared with RMB 196,000 (unaudited) for the same period in 2023. The increase in credit impairment losses was primarily due to the increase in the number of patients and the corresponding increase in the Company's credit exposure.

Management Discussion and Analysis

Non-Operating Income and Non-Operating Expenses

For the six months ended June 30, 2024, the Company's non-operating income was RMB 1,234,567 (Unaudited), and non-operating expenses were RMB 567,890 (Unaudited). The net non-operating income was RMB 666,677 (Unaudited). The non-operating income mainly consisted of government subsidies, interest income, and other income. The non-operating expenses mainly consisted of asset impairment losses, donation expenses, and other expenses.

For the six months ended June 30,	
2024	2023
(RMB' 000)	(B'000)
(Unaudited)	(- 0.00)

Management Discussion and Analysis

Fixed Assets

Inventory

At December 31, 2024, the carrying amount of inventory was RMB51.9 million (December 31, 2023: RMB60.6 million), which was mainly composed of medical supplies and pharmaceuticals.

Accounts Receivables

At December 31, 2024, the carrying amount of accounts receivables was RMB448.1 million (December 31, 2023: RMB420.4 million), of which the provision for bad debts was RMB26.6 million (December 31, 2023: RMB26.6 million). The provision for bad debts was calculated based on the expected credit loss model.

The carrying amount of accounts receivables was RMB448.1 million at December 31, 2024, compared with RMB420.4 million at December 31, 2023, an increase of RMB27.7 million, mainly due to the increase in the carrying amount of accounts receivables from medical services.

Other Receivables and Prepayments

At December 31, 2024, the carrying amount of other receivables and prepayments was RMB72.3 million (December 31, 2023: RMB79.5 million), which was mainly composed of prepayments for medical services and other receivables.

Other Non-current Financial Assets

At December 31, 2024, the carrying amount of other non-current financial assets was RMB64.8 million (December 31, 2023: RMB65.1 million), which was mainly composed of long-term equity investments and other non-current financial assets.

Construction in progress

At December 31, 2024, the carrying amount of construction in progress was RMB234.0 million (December 31, 2023: RMB187.0 million). The carrying amount of construction in progress was mainly composed of the construction of new hospitals and the renovation of existing hospitals.

Right-of-use Assets

At December 31, 2024, the carrying amount of right-of-use assets was RMB170.5 million (December 31, 2023: RMB189.1 million), which was mainly composed of right-of-use assets for medical services and other right-of-use assets.

Accounts Payables

At December 31, 2024, the carrying amount of accounts payables was RMB112.5 million (December 31, 2023: RMB110.1 million), which was mainly composed of accounts payable for medical services and other accounts payable.

Management Discussion and Analysis

Receipts in Advance and Contract Liabilities

As of June 30, 2024, the amount of Receipts in Advance and Contract Liabilities was RMB26.3 million (June 30, 2023: RMB26.6 million).

Other Payables

As of June 30, 2024, the amount of Other Payables was RMB68.5 million (June 30, 2023: RMB150.3 million). The decrease was mainly due to the payment of the advance payment for the purchase of medical equipment.

	For the six months ended June 30,	
	2024	2023
	(RMB'000)	(RMB'000)
	(Unaudited)	(Unaudited)
Operating activities	116,536	113,591
Investing activities	-112,711	-119,122
Financing activities	-41,660	9,790
Net change in cash and cash equivalents	-37,934	4,273

Net Cash Generated from Operating Activities

During the six months ended June 30, 2024, the net cash generated from operating activities was RMB116.5 million (June 30, 2023: RMB113.6 million). The increase was mainly due to the increase in the net cash generated from operating activities, which was RMB45.0 million (June 30, 2023: RMB5.6 million). The increase was mainly due to the increase in the net cash generated from operating activities, which was RMB79.4 million (June 30, 2023: RMB42.4 million).

Net Cash Used in Investing Activities

During the six months ended June 30, 2024, the net cash used in investing activities was RMB112.7 million (June 30, 2023: RMB111.0 million). The increase was mainly due to the increase in the net cash used in investing activities, which was RMB11.0 million (June 30, 2023: RMB11.0 million). The increase was mainly due to the increase in the net cash used in investing activities, which was RMB11.0 million (June 30, 2023: RMB11.0 million).



Management Discussion and Analysis

Net Cash Generated from Financing Activities

[illegible]

Significant Investment, Acquisition and Disposal

G • 1 11 1 1 1 1 1 1 1 1 1 1 1 J 30, 2024.

A  B 

Bank Borrowings

A J 30, 2024, G B923.3 (D
31, 2023: B864.7 B304.8
B363.4

Contingent Liability

A J 30, 2024, G

Asset Pledge

D₀ (2016) E .0010144, (2016) E .0010142, (2021)
E .0081628, G (2015) .1-11836, G (2015) .1-11833
C₀ 0018361 C₀ ICBC B₀ (2017) C C E
B267.3 (2020) E .0068897 C₀ B C C₀ C₀ A
J₀ 30, 2024, B95.0 J₀ H₀ .0002503
(2022) J₀ E .331122202000043 J₀
C₀ B₀ A J₀ 30, 2024, B25.0
H₀ .0045588 C₀ CI IC B₀ A J₀ 30, 2024,
B58.3

Management Discussion and Analysis

Lease Liabilities

As of December 31, 2024, the Company's lease liabilities were RMB22.8 million, compared with RMB158.9 million as of December 31, 2023. The decrease is primarily due to the completion of the lease term for the Company's leased premises.

Financial Instruments

The Company's financial instruments are primarily cash, accounts receivable, accounts payable, and other receivables. The Company's financial instruments are classified as financial assets and financial liabilities. The Company's financial instruments are measured at fair value.

Exposure to Fluctuation in Exchange Rates

The Company's financial statements are presented in RMB. The Company's financial statements are prepared in accordance with the accounting standards of the People's Republic of China. The Company's financial statements are audited by a qualified accounting firm. The Company's financial statements are subject to the audit opinion of the accounting firm.

Gearing Ratio

As of December 31, 2024, the Company's gearing ratio was 52.6% (December 31, 2023: 53.8%).

Employees and Remuneration Policy

As of December 31, 2024, the Company had 4,742 employees (December 31, 2023: 4,765 employees). The Company's remuneration policy is based on the Company's performance and the market conditions. The Company's remuneration policy is subject to the approval of the Company's Board of Directors.

The Company's remuneration policy is based on the Company's performance and the market conditions. The Company's remuneration policy is subject to the approval of the Company's Board of Directors.

Management Discussion and Analysis

本公司自2018年起，根據《溫州康寧醫院股份有限公司2018年股權激勵計劃》（Equity Incentive Scheme），實施了股權激勵計劃。該計劃旨在吸引和留住核心管理人員及技術人員，激發其工作積極性，提高公司競爭力。根據該計劃，本公司在2018年授予了165名激勵對象合計1,818,529股限制性股票。截至2021年12月31日，該計劃已實施完畢。在2018年至2021年期間，該計劃對公司業績產生了積極影響，激勵對象的工作積極性顯著提高，公司競爭力得到進一步增強。此外，該計劃還有助於吸引和留住核心人才，為公司的長期發展奠定了堅實的人才基礎。

截至2021年12月31日，該計劃已實施完畢。在2018年至2021年期間，該計劃對公司業績產生了積極影響，激勵對象的工作積極性顯著提高，公司競爭力得到進一步增強。此外，該計劃還有助於吸引和留住核心人才，為公司的長期發展奠定了堅實的人才基礎。根據該計劃，本公司在2018年授予了165名激勵對象合計1,818,529股限制性股票。截至2021年12月31日，該計劃已實施完畢。在2018年至2021年期間，該計劃對公司業績產生了積極影響，激勵對象的工作積極性顯著提高，公司競爭力得到進一步增強。此外，該計劃還有助於吸引和留住核心人才，為公司的長期發展奠定了堅實的人才基礎。

截至2021年12月31日，該計劃已實施完畢。在2018年至2021年期間，該計劃對公司業績產生了積極影響，激勵對象的工作積極性顯著提高，公司競爭力得到進一步增強。此外，該計劃還有助於吸引和留住核心人才，為公司的長期發展奠定了堅實的人才基礎。根據該計劃，本公司在2018年授予了165名激勵對象合計1,818,529股限制性股票。截至2021年12月31日，該計劃已實施完畢。在2018年至2021年期間，該計劃對公司業績產生了積極影響，激勵對象的工作積極性顯著提高，公司競爭力得到進一步增強。此外，該計劃還有助於吸引和留住核心人才，為公司的長期發展奠定了堅實的人才基礎。

Management Discussion and Analysis

• 一、报告期内主要经营情况

(1) 主营业务

报告期内，公司紧紧围绕“以患者为中心”的经营理念，坚持“质量、安全、服务”三大宗旨，不断提升医疗服务水平。在业务拓展方面，公司积极开拓基层市场，通过多点执业、远程会诊等方式，扩大服务半径。在学科建设方面，公司加大投入，引进高层次人才，提升专科实力。在运营管理方面，公司优化流程，提高效率，降低运营成本。报告期内，公司实现营业收入XX万元，同比增长XX%；实现净利润XX万元，同比增长XX%。主要业务板块表现如下：

（一）医疗服务

报告期内，公司共完成门诊诊疗XX人次，住院诊疗XX人次。其中，内科、外科、妇产科、儿科等核心科室业务量稳步增长。公司积极开展“互联网+医疗”服务，通过线上问诊、远程会诊等方式，提升患者就医体验。报告期内，公司共开展远程会诊XX例，线上问诊XX人次。

（二）药品销售

报告期内，公司药品销售收入XX万元，同比增长XX%。公司严格执行国家药品集中采购政策，确保药品质量，降低采购成本。同时，公司积极推广创新药、仿制药，满足患者用药需求。

（三）医疗器械销售

报告期内，公司医疗器械销售收入XX万元，同比增长XX%。公司主要销售超声、CT、MRI等大型医疗设备，以及各类医用耗材。公司加强与上游供应商的合作，确保设备质量，降低采购成本。

(2)

(一)

A、报告期内，公司实现营业收入XX万元，同比增长XX%。其中，医疗服务收入XX万元，同比增长XX%；药品销售收入XX万元，同比增长XX%；医疗器械销售收入XX万元，同比增长XX%。

B、报告期内，公司实现净利润XX万元，同比增长XX%。其中，医疗服务利润XX万元，同比增长XX%；药品销售利润XX万元，同比增长XX%；医疗器械销售利润XX万元，同比增长XX%。

C、报告期内，公司总资产XX万元，同比增长XX%。其中，流动资产XX万元，同比增长XX%；非流动资产XX万元，同比增长XX%。

D、报告期内，公司净资产XX万元，同比增长XX%。其中，所有者权益XX万元，同比增长XX%；负债XX万元，同比增长XX%。

E、报告期内，公司经营活动产生的现金流量净额XX万元，同比增长XX%。其中，销售商品、提供劳务收到的现金XX万元，同比增长XX%；购买商品、接受劳务支付的现金XX万元，同比增长XX%。

(二)

B、报告期内，公司实现营业收入XX万元，同比增长XX%。其中，医疗服务收入XX万元，同比增长XX%；药品销售收入XX万元，同比增长XX%；医疗器械销售收入XX万元，同比增长XX%。

Management Discussion and Analysis

[illegible][illegible]

C

Wiederholung des ersten Teils.

Wiederholung des zweiten Teils.

Wiederholung des dritten Teils.

Wiederholung des vierten Teils.

Wiederholung des fünften Teils.

Wiederholung des sechsten Teils.

Wiederholung des siebten Teils.

Wiederholung des achten Teils.

Wiederholung des neunten Teils.

Wiederholung des zehnten Teils.

Wiederholung des elften Teils.

Wiederholung des zwölften Teils.

Wiederholung des dreizehnten Teils.

Wiederholung des vierzehnten Teils.

Wiederholung des fünfzehnten Teils.

Wiederholung des sechzehnten Teils.

Wiederholung des siebenzehnten Teils.

Wiederholung des achtzehnten Teils.

Wiederholung des neunzehnten Teils.

Wiederholung des zwanzigsten Teils.

Wiederholung des einundzwanzigsten Teils.

Wiederholung des zweiundzwanzigsten Teils.

Wiederholung des dreiundzwanzigsten Teils.

Wiederholung des vierundzwanzigsten Teils.

Wiederholung des fünfundzwanzigsten Teils.

Wiederholung des sechsundzwanzigsten Teils.

Wiederholung des siebenundzwanzigsten Teils.

Wiederholung des achtundzwanzigsten Teils.

Wiederholung des neunundzwanzigsten Teils.

Wiederholung des hundertsten Teils.

[illegible]

Figure 1: Schematic representation of the experimental design. The figure is divided into two main sections: 'D' (Dissociation) and 'C' (Control). Section 'D' shows a sequence of events: a subject is presented with a stimulus (a circle with a dot), then a response is recorded (a circle with a dot), and finally, the subject is asked to identify the stimulus (a circle with a dot). Section 'C' shows a sequence of events: a subject is presented with a stimulus (a circle with a dot), then a response is recorded (a circle with a dot), and finally, the subject is asked to identify the stimulus (a circle with a dot). The figure is labeled 'Figure 1' and 'Schematic representation of the experimental design'.

() A $\frac{7}{8}$ C $\frac{9}{10}$

E

2,460,000

[illegible]

() 9 9 5 9 5 9 9

[illegible]

(c) $\Delta \theta = 0$, $E_{\text{eff}} = 0$

48

() - 2 2 2 2

48 (J. 7 28, 2022).

[illegible]

Management Discussion and Analysis

As of June 30, 2024, the Company has issued 10,000,000 shares of ordinary shares, of which 10,000,000 shares are held by the Company and 0 shares are held by other shareholders.

Name/Category of Grantee	Date of Grant	Vesting Date (Unlocking Date)	Grant Price (RMB/Share)	Balance of Incentive Shares	Balance of Incentive Shares	Granted during the Reporting Period	Vested (Unlocked) during the Reporting Period	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Balance of Incentive Shares
				Granted but not Vested as at January 1, 2024	Granted and Vested as at January 1, 2024					Granted but not Vested as at June 30, 2024
Director										
Mr. A G	Jan 18, 2021	Jan 28, 2022	10.47		248,328					
Mr. IE	Jan 18, 2021	Jan 28, 2022	10.47		4,776					
Mr. A G H	Jan 18, 2021	Jan 28, 2022	10.47		28,653					
Mr. A G H	Jan 18, 2021	Jan 28, 2022	10.47		95,511					
Mr. A G B ()	Jan 18, 2021	Jan 28, 2022	10.47		4,776					
Mr. A G H	Jan 18, 2021	Jan 28, 2022	10.47		4,776					
Mr. G A	Jan 18, 2021	Jan 28, 2022	10.47							

Management Discussion and Analysis

Name/Category of Grantee	Date of Grant	Vesting Date (Unlocking Date)	Grant Price (RMB/ Share)	Balance of	Balance of	Granted during the Reporting Period	Vested (Unlocked) during the Reporting Period	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Balance of
				Granted but not Vested as at January 1, 2024	Granted and Vested as at January 1, 2024					Incentive Shares Granted but not Vested as at June 30, 2024
董事、高级管理人员及核心技术人员	A	2018	2022	10.47		133,715				
C类股权激励对象	A	2021	2022	10.47		47,755				
C类股权激励对象	A	2018	2022	10.47		1,605,540				
B类股权激励对象	A	2019	2022	10.47		180,516				
A类股权激励对象	A	2021	2022	10.47		36,886				
					2,460,000					

A类股权激励对象是指公司高级管理人员及核心技术人员，D类股权激励对象是指公司高级管理人员及核心技术人员，C类股权激励对象是指公司高级管理人员及核心技术人员。

H类股权激励对象是指公司高级管理人员及核心技术人员，A类股权激励对象是指公司高级管理人员及核心技术人员，B类股权激励对象是指公司高级管理人员及核心技术人员，C类股权激励对象是指公司高级管理人员及核心技术人员。

2023年12月27日，公司召开2023年第三次临时股东大会，审议通过了《关于向公司高级管理人员及核心技术人员授予限制性股票的议案》，同意公司向公司高级管理人员及核心技术人员授予限制性股票。2023年12月27日，公司向公司高级管理人员及核心技术人员授予了限制性股票。2024年1月12日，公司向公司高级管理人员及核心技术人员授予了限制性股票。2024年1月23日，公司向公司高级管理人员及核心技术人员授予了限制性股票。2024年1月18日，公司向公司高级管理人员及核心技术人员授予了限制性股票。

Management Discussion and Analysis

I, H, A, 36, 364,100, 36, 616,000, 52, 335,000, 75,000, 7, 1,240,100, 1.66%, 8, 2023, 27, 2023, A, 12, 2024, A, 23, 2024, J, 18, 2024.

Corporate Governance and Other Information

C / A E G E A CE

D... CGC...

C / IA CE I H HE DE C DE

C... 2024 J 30, 2024

Corporate Governance and Other Information

ALDI C I EE A D E IE F HE I E I E, A D HE I E I E _

C 3.21 3.22 H
CG C
A J 30, 2024, A
D H G (A) J
D IC A G
J 30, 2024

I E I DI IDE D

B 2024 (B
C), B1.50 (10
A I E I E A CE E F
HE I H E DED J E 30, 2024 C 74,600,300
E 751,900 H C
B11,077,260 (21.81%
D B H H
D H B C
B EG C
2024 EG C
D EG
I D 18, 2024.

Corporate Governance and Other Information

CHA GE I DI EC , - , E I A D E I A AGE E

Wenzhou Kangning Hospital Co., Ltd. is a public company listed on the Shanghai Stock Exchange (600826). The company is committed to corporate governance and transparency, and has established a complete system of corporate governance.

E E AF E HE E I G, E I D

The company has established a complete system of corporate governance, including the Constitution, Articles of Association, and various internal control systems. The company is committed to corporate governance and transparency, and has established a complete system of corporate governance.

CHA GE I DI EC , - , E I ' A D CHIEF E EC_ I E'
BI G A, HICA DE AI

The company has established a complete system of corporate governance, including the Constitution, Articles of Association, and various internal control systems. The company is committed to corporate governance and transparency, and has established a complete system of corporate governance.

Name	Members of the Group	Positions held at members of the Group	Term of office
A G 1	G 1 F	E 1 D 1 W 1	F 1 2024 1
A G J 1	H 1 C 1 .	E 1 D 1 W 1	F 1 A 1 2024 1

The company has established a complete system of corporate governance, including the Constitution, Articles of Association, and various internal control systems. The company is committed to corporate governance and transparency, and has established a complete system of corporate governance.

(3) 上海金浙企业管理中心(有限合伙)持有上海金浙企业管理中心(有限合伙) 50%的股权。上海金浙企业管理中心(有限合伙)持有上海金浙企业管理中心(有限合伙) 50%的股权。上海金浙企业管理中心(有限合伙)持有上海金浙企业管理中心(有限合伙) 50%的股权。

Corporate Governance and Other Information

As of December 31, 2024, the Company has a total of 100,000,000 shares outstanding, all of which are ordinary shares. The Company's shares are listed on the Shanghai Stock Exchange. The Company's shares are held by various investors, including institutional investors and individual investors. The Company's shares are subject to the same rights and obligations as the shares of the Company's parent company, Wenzhou Kangning Hospital Co., Ltd.

Interests of Substantial Shareholders

As of December 31, 2024, the Company has identified the following substantial shareholders: (1) Wenzhou Kangning Hospital Co., Ltd. (the "Parent Company") holds 7,466,666 shares, representing approximately 7.47% of the total issued shares. (2) Shanghai Jinzhen Enterprise Management Center (Limited Partnership) holds 4,540,000 shares, representing approximately 4.54% of the total issued shares. (3) FA (2) holds 4,540,000 shares, representing approximately 4.54% of the total issued shares. (4) J (2) holds 4,540,000 shares, representing approximately 4.54% of the total issued shares.

Name	Class of Shares	Nature of Interest	Number of Shares	Approximate	Approximate
				Percentage in Shares of the Same Class ⁽¹⁾	Percentage of the Company's Total Issued Shares Capital ⁽¹⁾
C E I F G (Central Enterprise Township Industry Investment Fund Co., Ltd.)	D	B	7,466,666 ()	13.51%	10.00%
上海金浙企业管理中心(有限合伙) ⁽²⁾	D	I	4,540,000 ()	8.22%	6.09%
FA ⁽²⁾	D	I	4,540,000 ()	8.22%	6.09%
J ⁽²⁾	D	I	4,540,000 ()	8.22%	6.09%

Corporate Governance and Other Information

Name	Class of Shares	Nature of Interest	Number of Shares	Approximate Percentage in Shares of the Same Class ⁽¹⁾	Approximate Percentage of the Company's Total Issued Shares Capital ⁽¹⁾
上海金浦健服股權投資管理有限公司 ⁽²⁾	D 類 股 份	直接持有	4,540,000 ()	8.22%	6.09%
溫州金寧股權投資合夥企業(有限合夥)	D 類 股 份	直接持有	4,540,000 ()	8.22%	6.09%
- ⁽⁶⁾	D 類 股 份	直接持有	3,984,350 ()	7.21%	5.34%
上海檀英投資合夥企業(有限合夥)	D 類 股 份	直接持有	4,519,003 ()	8.18%	6.06%
上海樂進投資合夥企業(有限合夥) ⁽³⁾	D 類 股 份	直接持有	4,519,003 ()	8.18%	6.06%
上海正心谷投資管理有限公司	D 類 股 份	直接持有	6,506,309 ()	11.77%	8.72%
上海盛歌投資管理有限公司 ⁽⁴⁾	D 類 股 份	直接持有	6,506,309 ()	11.77%	8.72%
萬得信息技術股份有限公司	D 類 股 份	直接持有	3,333,000 ()	6.03%	4.47%
上海荷花緣企業管理中心(有限合夥)	D 類 股 份	直接持有	3,333,000 ()	6.03%	4.47%

Corporate Governance and Other Information

Name	Class of Shares	Nature of Interest	Number of Shares	Approximate Percentage in Shares of the Same Class ⁽¹⁾	Approximate Percentage of the Company's Total Issued Shares Capital ⁽¹⁾
Wind Investment (Wind Investment) (萬得影響力股權投資(嘉興)合夥企業(有限合夥))	D	B	3,333,000()	6.03%	4.47%
CI IC (中信證券投資有限公司)	D	B	2,780,000()	5.03%	3.73%
CI IC (中信證券股份有限公司) ⁽⁵⁾	D	I	2,780,000()	5.03%	3.73%
Wang A C	H	I	1,454,000()	7.52%	1.95%
Wang C C	H	I	2,150,900()	11.12%	2.88%
Wang F C	H	B	1,279,900()	6.62%	1.72%
Wang II, J.	H	B	1,052,000()	5.44%	1.41%
- B G AG	H	I	1,029,400()	5.32%	1.38%
- H (鄒海麗)	H	B	1,680,000()	8.69%	2.25%
A G H ⁽⁶⁾	D	B	3,984,350()	7.21%	5.34%
	H	B	309,000()	1.60%	0.41%
H C	H	I	1,547,500()	8.00%	2.07%
C (H)	H		1,547,500()	8.00%	2.07%

Corporate Governance and Other Information

:

(): 77

(1) 74,600,300 55,260,000 D 19,340,300 H (30, 2024.

(2) FA 50% 77 E C (上海金浙企業管理中心(有限合夥)) 77 E C (上海金浙企業管理中心(有限合夥)) 77 E 33.94% 77 (溫州金寧股權投資合夥企業(有限合夥)). 77 77 E 77 C., 77. (上海金浦健服股權投資管理有限公司) 77 E 77 (上海金浙企業管理中心(有限合夥)). F, FA 77 E C (上海金浙企業管理中心(有限合夥)), 77 77 E 77 C., 77. (上海金浦健服股權投資管理有限公司) 77 D 77 77 77 (溫州金寧股權投資合夥企業(有限合夥)) 77 C.

(3) 77 (上海樂進投資合夥企業(有限合夥)) 99.99% 77 (上海檀英投資合夥企業(有限合夥)). F, 77 (上海樂進投資合夥企業(有限合夥)) 77 D 77 (上海檀英投資合夥企業(有限合夥)) 77 C.

(4) 77 C., 77. (上海正心谷投資管理有限公司) 77 (上海盛歌投資管理有限公司) 77 (上海乾剛投資管理合夥企業(有限合夥)) 77 (上海檀英投資合夥企業(有限合夥)). F, 77 C., 77. (上海乾剛投資管理合夥企業(有限合夥)) D 77 1,987,356 D 77 C.) 77 (上海檀英投資合夥企業(有限合夥)) 77 C.

(5) CI IC 77 (中信証券投資有限公司) 77 CI IC 77 C 77 F, CI IC 77 C 77 D 77 CI IC 77 (中信証券投資有限公司) 77 C.

(6) 77 A G H 77 D 77 A G H 77 F.

16, 2024

Consolidated Balance Sheets

J 30, 2024
(A 1 1 B 1)

		Balance as at the end of the period	B
ASSETS	I		
Current assets:			
C	()	373,302,433.47	418,861,721.39
/			
F 1	()	7,599,178.13	7,350,298.53
D			
A	()	763,849.74	
A	()	448,102,421.02	420,441,069.56
A	()	2,366,951.74	9,830,552.98
/			
/			
/	()	69,943,027.66	69,705,728.98
F 1			
I	()	51,889,640.76	60,600,180.25
I			
C			
A			
/	()	3,053,787.78	858,020.39
Total current assets		957,021,290.30	987,647,572.08

Consolidated Balance Sheets

J 30, 2024
(A B)

	Balance as at the end of the period	B
ASSETS		
Non-current assets:		
G		
D		
	() 14,000,000.00	14,000,000.00
	() 141,550,815.01	139,071,987.05
I	() 64,751,652.55	65,099,055.34
I	() 782,127,103.00	794,856,342.94
F	() 234,034,296.61	186,980,240.67
C		
	() 170,465,125.54	189,054,506.68
I	() 307,875,476.38	320,321,705.16
I : D		
D		
I : D		
G	() 119,909,089.24	119,909,089.24
	() 156,750,581.45	175,910,626.14
D	() 44,940,518.91	45,146,270.60
	() 14,925,823.45	9,689,210.94
Total non-current assets	2,051,330,482.14	2,060,039,034.76
Total assets	3,008,351,772.44	3,047,686,606.84

GUAN Weili

JIN Hui

H WANG Minhui

Consolidated Balance Sheets

June 30, 2024

(A) (B)

		Balance as at the end of the period	B
LIABILITIES AND SHAREHOLDERS' EQUITY	I		
Current liabilities:			
B	()	111,000,000.00	127,001,700.00
F	()	12,400,000.00	12,400,000.00
D			1,545,021.09
A	()	112,544,938.03	110,060,007.67
C	()	26,157,511.69	26,563,603.06
F	()	92,924.53	
F			
F			
E	()	67,014,464.52	84,324,006.40
F	()	30,855,445.81	38,553,746.47
F	()	68,487,137.05	150,270,575.15
F			
F			
F	()	108,286,381.25	250,411,756.99
F	()	569,425.21	
Total current liabilities		537,408,228.09	801,130,416.83
Non-current liabilities:			
B	()	768,224,669.65	557,719,214.69
B			
I			
I	()	158,912,952.10	163,239,532.76
I	()	64,227,913.88	61,351,340.53
D	()	8,582,203.00	8,734,099.00
D	()	44,533,949.56	47,306,056.21
Total non-current liabilities		1,044,481,688.19	838,350,243.19

(A)  (B) 

	Balance as at the end of the period	B
LIABILITIES AND SHAREHOLDERS' EQUITY		
Total liabilities	1,581,889,916.28	1,639,480,660.02
Shareholders' equity:		
Capital	() 74,600,300.00	74,600,300.00
Reserves		
- General reserve	() 840,753,480.74	852,695,601.69
- Special reserve	() 3,146,832.71	12,587,011.74
- Other reserves		
- Surplus	() 38,399,577.13	38,399,577.13
- Other	() 340,299,883.36	311,956,229.16
Total equity attributable to shareholders of the parent company	1,290,906,408.52	1,265,064,696.24
Non-controlling interests	135,555,447.64	143,141,250.58
Total shareholders' equity	1,426,461,856.16	1,408,205,946.82
Total liabilities and shareholders' equity	3,008,351,772.44	3,047,686,606.84

GUAN Weili JIN Hui WANG Minhui

Parent Company Balance Sheets

J 30, 2024
(A 1 1 B 1)

	Balance as at the end of the period	B
ASSETS		
Current assets:		
C	167,239,404.12	186,837,559.21
F 1		
D 1 1 1 1		
A	(1) 55,989,746.68	48,066,557.69
A	6,900.00	228,131.12
I	(11) 622,922,583.60	600,448,325.58
I 1 : D	9,687,901.11	11,181,002.59
C		
A		
	355,000.00	330,000.00
Total current assets	856,201,535.51	847,091,576.19

(A) (B)

WANG Minhui

Parent Company Balance Sheets

J 30, 2024
(A 11B)

	Balance as at the end of the period	B
LIABILITIES AND SHAREHOLDERS' EQUITY	I	11B
Current liabilities:		
111,000,000.00	111,000,000.00	125,000,000.00
F 111,000,000.00		
D 111,000,000.00		
A	37,382,041.07	33,774,329.53
3,483,707.09	3,483,707.09	4,172,410.35
C 111,000,000.00		
E 16,652,661.89	16,652,661.89	20,572,854.31
2,812,623.38	2,812,623.38	1,603,746.33
42,052,422.61	42,052,422.61	38,919,608.73
59,854,608.34	59,854,608.34	173,615,500.00
Total current liabilities	273,238,064.38	397,658,449.25
Non-current liabilities:		
506,300,000.00	506,300,000.00	362,042,127.25
B		
I		
16,710,574.36	16,710,574.36	25,855,234.63
8,582,203.00	8,582,203.00	8,734,099.00
Total non-current liabilities	531,592,777.36	396,631,460.88
Total liabilities	804,830,841.74	794,289,910.13

Item		Amount for the current period	Amount for the corresponding period
I. Total revenue	()	828,957,553.71	777,925,163.84
I. 1. Total revenue	()	828,957,553.71	777,925,163.84
I. 1. 1. Total revenue			
I. 1. 2. Total revenue			
I. 1. 3. Total revenue			
I. 1. 4. Total revenue			
I. 1. 5. Total revenue			
I. 1. 6. Total revenue			
I. 1. 7. Total revenue			
I. 1. 8. Total revenue			
I. 1. 9. Total revenue			
I. 1. 10. Total revenue			
I. 1. 11. Total revenue			
I. 1. 12. Total revenue			
I. 1. 13. Total revenue			
I. 1. 14. Total revenue			
I. 1. 15. Total revenue			
I. 1. 16. Total revenue			
I. 1. 17. Total revenue			
I. 1. 18. Total revenue			
I. 1. 19. Total revenue			
I. 1. 20. Total revenue			
I. 1. 21. Total revenue			
I. 1. 22. Total revenue			
I. 1. 23. Total revenue			
I. 1. 24. Total revenue			
I. 1. 25. Total revenue			
I. 1. 26. Total revenue			
I. 1. 27. Total revenue			
I. 1. 28. Total revenue			
I. 1. 29. Total revenue			
I. 1. 30. Total revenue			
I. 1. 31. Total revenue			
I. 1. 32. Total revenue			
I. 1. 33. Total revenue			
I. 1. 34. Total revenue			
I. 1. 35. Total revenue			
I. 1. 36. Total revenue			
I. 1. 37. Total revenue			
I. 1. 38. Total revenue			
I. 1. 39. Total revenue			
I. 1. 40. Total revenue			
I. 1. 41. Total revenue			
I. 1. 42. Total revenue			
I. 1. 43. Total revenue			
I. 1. 44. Total revenue			
I. 1. 45. Total revenue			
I. 1. 46. Total revenue			
I. 1. 47. Total revenue			
I. 1. 48. Total revenue			
I. 1. 49. Total revenue			
I. 1. 50. Total revenue			
I. 1. 51. Total revenue			
I. 1. 52. Total revenue			
I. 1. 53. Total revenue			
I. 1. 54. Total revenue			
I. 1. 55. Total revenue			
I. 1. 56. Total revenue			
I. 1. 57. Total revenue			
I. 1. 58. Total revenue			
I. 1. 59. Total revenue			
I. 1. 60. Total revenue			
I. 1. 61. Total revenue			
I. 1. 62. Total revenue			
I. 1. 63. Total revenue			
I. 1. 64. Total revenue			
I. 1. 65. Total revenue			
I. 1. 66. Total revenue			
I. 1. 67. Total revenue			
I. 1. 68. Total revenue			
I. 1. 69. Total revenue			
I. 1. 70. Total revenue			
I. 1. 71. Total revenue			
I. 1. 72. Total revenue			
I. 1. 73. Total revenue			
I. 1. 74. Total revenue			
I. 1. 75. Total revenue			
I. 1. 76. Total revenue			
I. 1. 77. Total revenue			
I. 1. 78. Total revenue			
I. 1. 79. Total revenue			
I. 1. 80. Total revenue			
I. 1. 81. Total revenue			
I. 1. 82. Total revenue			
I. 1. 83. Total revenue			
I. 1. 84. Total revenue			
I. 1. 85. Total revenue			
I. 1. 86. Total revenue			
I. 1. 87. Total revenue			
I. 1. 88. Total revenue			
I. 1. 89. Total revenue			
I. 1. 90. Total revenue			
I. 1. 91. Total revenue			
I. 1. 92. Total revenue			
I. 1. 93. Total revenue			
I. 1. 94. Total revenue			
I. 1. 95. Total revenue			
I. 1. 96. Total revenue			
I. 1. 97. Total revenue			
I. 1. 98. Total revenue			
I. 1. 99. Total revenue			
I. 1. 100. Total revenue			
I. 1. 101. Total revenue			
I. 1. 102. Total revenue			
I. 1. 103. Total revenue			
I. 1. 104. Total revenue			
I. 1. 105. Total revenue			
I. 1. 106. Total revenue			
I. 1. 107. Total revenue			
I. 1. 108. Total revenue			
I. 1. 109. Total revenue			

Consolidated Income Statement

For the period from January 1 to December 31, 2024

(A: Amount in thousands of RMB; B: Amount in millions of RMB)

Item	Amount for the current period	Amount for the corresponding period of the previous year
III. Operating profit (losses represented with "-" sign)	63,825,306.45	56,497,282.53
Add: Other income	(7) 503,489.95	5,924,960.98
Less: Other expenses	(7) 2,816,219.76	2,215,131.37
IV. Total profit (total losses represented with "-" signs)	61,512,576.64	60,207,112.14
Less: Income tax expense	(7) 16,516,143.35	11,477,880.07
V. Net profit (net losses represented with "-" signs)	44,996,433.29	48,729,232.07
(1) C: Net profit attributable to shareholders of the company		
1. Net profit attributable to shareholders of the company	44,996,433.29	48,729,232.07
2. Net profit attributable to shareholders of the company		
(2) C: Net profit attributable to shareholders of the company		
1. Net profit attributable to shareholders of the company	50,723,744.20	43,750,057.46
2. Net profit attributable to shareholders of the company	-5,727,310.91	4,979,174.61
VI. Other comprehensive income, net of tax		
(1) C: Other comprehensive income attributable to shareholders of the company		
1. C: Other comprehensive income attributable to shareholders of the company		
2. Other comprehensive income attributable to shareholders of the company		
3. C: Other comprehensive income attributable to shareholders of the company		
4. C: Other comprehensive income attributable to shareholders of the company		

Consolidated Income Statement

截至 2024 年 6 月 30 日
(A 股 和 B 股 均 以 人 民 币 元 为 单 位)

Item	I	Amount for the current period	A 股 人 民 币 元	B 股 人 民 币 元
(一) 营业收入				
1. 主营业务收入				
2. 其他业务收入				
3. 投资收益				
4. 公允价值变动收益				
5. 资产处置收益				
6. 其他收益				
7. 营业外收入				
(二) 营业成本				
1. 主营业务成本				
2. 其他业务成本				
3. 税金及附加				
4. 销售费用				
5. 管理费用				
6. 研发费用				
7. 财务费用				
8. 资产减值损失				
9. 信用减值损失				
10. 其他费用				
11. 营业外支出				
VII. Total comprehensive income		44,996,433.29	48,729,232.07	
A 股 人 民 币 元		50,723,744.20	43,750,057.46	
A 股 人 民 币 元		-5,727,310.91	4,979,174.61	
VIII. Earnings per share:				
(一) B 股 (B 股 人 民 币 元)	(元)	0.68	0.59	
(二) D 股 (B 股 人 民 币 元)	(元)	0.68	0.59	

GUAN Weili JIN Hui WANG Minhui

Parent Company Income Statement

For the period ending June 30, 2024

(Amount in thousands of RMB)

Item		Amount for the current period	Amount for the corresponding period of the previous year
I. Revenue	(1)	193,286,941.03	176,204,799.00
: C	(1)	130,785,130.41	130,786,397.79
•		3,245,018.31	140,434.74
•		421,415.53	613,098.03
G		33,439,820.06	42,010,452.24
•		12,778,787.81	9,690,626.11
F		7,528,437.05	8,063,326.82
I		13,692,407.18	11,787,407.21
I		8,491,601.94	6,124,076.98
A		2,425,821.83	1,314,851.41
I	()	14,189,338.60	-775,547.72
I		128,019.62	816,165.55
D			
G			
G			
C			
A			
G			
G		-347,402.79	
C		6,859,241.73	114,004.00
A			
G			
II. Operating profit (losses represented with "-" signs)		28,215,331.23	-14,446,229.04
A			5,600,210.07
:		321,888.39	1,517,392.82
III. Total profit (total losses represented with "-" signs)		27,893,442.84	-10,363,411.79
:I		-1,490,906.78	-1,686,567.50
IV. Net profit (net losses represented with "-" signs)		29,384,349.62	-8,676,844.29
(1)		29,384,349.62	-8,676,844.29
(2)			

Parent Company Income Statement

From January 1, 2024 to June 30, 2024
(Amount in thousands of RMB)

Item	Amount for the current period	Amount for the corresponding period of the previous year
V. Other comprehensive income, net of tax		
(1) Other comprehensive income		
1. C		
2.		
3. C		
4. C		
(2) Other comprehensive income		
1.		
2. C		
3. A		
4. C		
5.		
6. E		
7.		
VI. Total comprehensive income	29,384,349.62	-8,676,844.29
VII. Earnings per share:		
(1) Basic earnings per share		
(2) Diluted earnings per share		

Prepared by: GUAN Weili Reviewed by: JIN Hui Approved by: WANG Minhui

Consolidated Cash Flow Statement

Ex 24 • J 30, 2024

(A) (B)

[illegible]

Consolidated Cash Flow Statement

人民币千元
(A 和 B 列示)

截至 2024 年 6 月 30 日

Item	Amount for the current period	Amount for the prior period
II. Cash flows from investing activities		
C 购买固定资产、无形资产和其他长期资产支付的现金	8,249,457.77	
C 处置固定资产、无形资产和其他长期资产收回的现金净额		
收回处置子公司、联营企业和合营企业投资收到的现金	644,865.42	26,383.01
收到其他与投资活动有关的现金	432,733.42	
C 取得子公司及其他营业单位支付的现金净额		
取得子公司支付的现金	1,077,598.84	8,275,840.78
C 收到其他与投资活动有关的现金		
收到处置子公司、联营企业和合营企业投资收到的现金	111,001,022.93	107,843,620.41
C 取得子公司及其他营业单位收到的现金净额	2,000,000.00	3,866,900.00
收到其他与投资活动有关的现金		
收到处置子公司、联营企业和合营企业投资收到的现金		15,187,013.06
C 取得子公司及其他营业单位支付的现金净额	787,500.00	500,059.94
收到其他与投资活动有关的现金	113,788,522.93	127,397,593.41

(A) (B)

Item	Amount for the current period	Amount for the prior period
IV. Effect of foreign exchange rate changes on cash and cash equivalents	-99,244.67	13,070.04
V. Net increase in cash and cash equivalents	-37,934,050.43	4,272,913.65
Amount at the beginning of the period	404,723,339.37	258,595,990.97
VI. Cash and cash equivalents at the end of the period	366,789,288.94	262,868,904.62

GUAN Weili JIN Hui WANG Minhui

Parent Company Cash Flow Statement

E 30, 2024

(A B)

Item	Amount for the current period	A
I. Cash flows from operating activities:		
C 178,625,474.28 186,510,657.37		
C 334,259,258.00 491,763,058.70		
Sub-total of cash inflows of operating activities	512,884,732.28	678,273,716.07
C 66,197,024.94 80,195,550.90		
C 84,545,764.25 80,891,274.33		
/ 2,949,959.92 438,877.67		
C 338,808,072.60 463,041,604.81		
Sub-total of cash outflows of operating activities	492,500,821.71	624,567,307.71
Net cash flows from operating activities	20,383,910.57	53,706,408.36
II. Cash flows from investing activities:		
C 16,657,744.50		
C 13,273,818.98		
10,427.00		
C 13,284,245.98 16,657,744.50		
Sub-total of cash inflows of investing activities	13,284,245.98	16,657,744.50
C 1,277,334.63 1,691,749.51		
C 7,200,000.00 29,166,900.00		
C 8,477,334.63 30,858,649.51		
Sub-total of cash outflows of investing activities	8,477,334.63	30,858,649.51
Net cash flows from investing activities	4,806,911.35	-14,200,905.01

Parent Company Cash Flow Statement

For the period from January 1 to June 30, 2024
(All amounts are in thousands of RMB)

Item	Amount for the current period	Amount for the corresponding period of the previous year
III. Cash flows from financing activities:		
Cash received from issuing shares		
Cash received from issuing shares	293,000,000.00	199,050,000.00
Cash received from issuing shares		
Sub-total of cash inflows of financing activities	293,000,000.00	199,050,000.00
Cash paid for acquiring subsidiaries		
Cash paid for acquiring subsidiaries	276,792,127.25	101,150,000.00
Cash paid for acquiring subsidiaries		
	35,406,263.84	12,364,450.26
Cash paid for acquiring subsidiaries	25,472,250.00	79,243,750.00
Sub-total of cash outflows of financing activities	337,670,641.09	192,758,200.26
Net cash flows from financing activities	-44,670,641.09	6,291,799.74
IV. Effect of foreign exchange rate changes on cash and cash equivalents	-119,720.72	13,070.04
V. Net increase in cash and cash equivalents	-19,599,539.89	45,810,373.13
Adjusted for the effect of foreign exchange rate changes	185,475,808.48	90,387,144.89
VI. Cash and cash equivalents at the end of the period	165,876,268.59	136,197,518.02

Prepared by: GUAN Weili Reviewed by: JIN Hui Approved by: WANG Minhui

Consolidated Statement of Changes in Shareholders' Equity

截至2024年6月30日止期间
(A) (B)

Amount for the current period													
Equity attributable to owners of the parent company													
Other equity instruments													
Items	Share capital	Preferential shares	Perpetual bonds	Others	Capital reserve	Less: Treasury stock	Other comprehensive income	Special reserves	Provision for general risk	Retained earnings	Subtotal	Minority interests	Total owners' equity
I. Balance as at the end of the previous year	74,600,300.00				862,666,601.69	12,367,011.74		38,394,577.13		311,956,229.16	1,265,061,696.24	143,141,250.58	1,408,205,946.82
II. Balance as at the beginning of the current year	74,600,300.00				862,666,601.69	12,367,011.74		38,394,577.13		311,956,229.16	1,265,061,696.24	143,141,250.58	1,408,205,946.82
III. Increases/decreases in the current period ("+" for increases)					-11,942,120.95	-9,440,179.03				28,343,654.20	25,841,712.28	-7,565,802.94	18,255,903.54
(1) Decreases in the current period					-8,666,709.51	-9,440,179.03				50,723,744.20	50,723,744.20	-5,727,310.91	44,996,433.29
1. Cash dividends paid					-9,334,383.19	-9,440,179.03					873,469.32	1,033,024.97	1,906,494.49
2. Cash dividends paid to minority shareholders											105,736.84	1,033,024.97	1,138,820.61
3. Cash dividends paid to minority shareholders													
4. Cash dividends paid to minority shareholders													
(2) Increases in the current period					767,673.68					-22,380,090.00	-22,380,090.00	-2,891,517.00	-25,271,607.00
1. Cash dividends paid													
2. Cash dividends paid to minority shareholders													
3. Cash dividends paid to minority shareholders													
4. Cash dividends paid to minority shareholders													
(3) Decreases in the current period													
1. Cash dividends paid													
2. Cash dividends paid to minority shareholders													
3. Cash dividends paid to minority shareholders													
4. Cash dividends paid to minority shareholders													
(4) Increases in the current period													
1. Cash dividends paid													
2. Cash dividends paid to minority shareholders													
3. Cash dividends paid to minority shareholders													
4. Cash dividends paid to minority shareholders													
IV. Balance as at the end of the period	74,600,300.00				840,724,480.74	3,146,832.71		38,394,577.13		340,299,883.36	1,290,906,408.32	135,555,447.64	1,426,461,666.16
(1) Decreases in the current period					-3,975,411.44					-3,975,411.44			-3,975,411.44
(2) Increases in the current period					840,724,480.74	3,146,832.71		38,394,577.13		340,299,883.36	1,290,906,408.32	135,555,447.64	1,426,461,666.16

GUAN Weili

JIN Hui

WANG Minhui

Consolidated Statement of Changes in Shareholders' Equity

截至 2024 年 6 月 30 日

(A) 人民币千元 (B) 美元

	期初余额	发行新股	发行可转换公司债券	回购	其他	期末余额
I. Balance as at the end of the previous year	74,600,300.00					74,600,300.00
A. 股本	685,076,533.30					685,076,533.30
B. 资本公积	233,506,534.43					233,506,534.43
C. 其他综合收益	12,387,011.74					12,387,011.74
D. 盈余公积	12,387,011.74					12,387,011.74
E. 未分配利润	1,201,584,944.86					1,201,584,944.86
II. Balance as at the beginning of the current year	74,600,300.00					74,600,300.00
III. Increases/decreases in the current period ("+" for increases)						
(一) 发行新股		38,889,577.13				38,889,577.13
(二) 发行可转换公司债券						
(三) 回购						
(四) 其他						
IV. Balance as at the end of the period	74,600,300.00	38,889,577.13				113,489,877.13

WANG Minhui

JIN Hui

GUAN Weili

Parent Company Statement of Changes in Shareholders' Equity

Feb 28, 2024

$$(A \rightarrow B) \rightarrow (A \rightarrow \neg B)$$

Items	Other equity instruments					Amount for the current period					
	Share capital	Preferential shares	Perpetual bonds	Others	Capital reserve	Treasury stock	Less: comprehensive income	Special reserves	Surplus reserves	Retained earnings	Total owners' equity
I. Balance as at the end of the previous year	74,600,300.00				871,230,628.64	12,587,011.74			38,399,577.13	284,123,941.46	1,255,767,435.49
II. Balance as at the beginning of the current year	74,600,300.00				871,230,628.64	12,587,011.74			38,399,577.13	284,123,941.46	1,255,767,435.49
III. Increases/decreases in the current period ("+" for increases)					-8,566,709.51	-9,440,179.03				7,004,259.62	7,877,729.14
1. C					-8,566,709.51	-9,440,179.03				29,384,349.62	29,384,349.62
2. C					-9,334,383.19	-9,440,179.03				7,004,259.62	7,877,729.14
3. F											
4. I											
(11) D					767,673.68						767,673.68
1. I											
2. I											
3. I											
(12) I											
1. C											
2. C											
3. C											
4. C											
5. C											
6. C											
(13) C											
1. I											
2. I											
(14) I											
Balance as at the end of the period	74,600,300.00				862,663,919.13	3,146,832.71			38,399,577.13	291,128,201.08	1,263,645,164.63

GUAN Weili

JIN Hui

H •
WANG Minhui

Parent Company Statement of Changes in Shareholders' Equity

截至2024年6月30日止期间
(A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z)

	股本	资本公积	其他综合收益	盈余公积	未分配利润	外币报表折算差额	其他权益工具	合计
I. Balance as at the end of the previous year	74,600,300.00							74,600,300.00
II. Balance as at the beginning of the current year	74,600,300.00							74,600,300.00
III. Increases/decreases in the current period ("+" for increases)								
(a) Issuance of new shares								
(b) Issuance of preferred shares								
(c) Conversion of preferred shares								
(d) Conversion of debt								
(e) Conversion of equity								
(f) Conversion of debt								
(g) Conversion of equity								
(h) Conversion of debt								
(i) Conversion of equity								
(j) Conversion of debt								
(k) Conversion of equity								
(l) Conversion of debt								
(m) Conversion of equity								
(n) Conversion of debt								
(o) Conversion of equity								
(p) Conversion of debt								
(q) Conversion of equity								
(r) Conversion of debt								
(s) Conversion of equity								
(t) Conversion of debt								
(u) Conversion of equity								
(v) Conversion of debt								
(w) Conversion of equity								
(x) Conversion of debt								
(y) Conversion of equity								
(z) Conversion of debt								
IV. Balance as at the end of the period	74,600,300.00							74,600,300.00

GUAN Weili
JIN Hui
WANG Minhui

Notes to the Financial Statements

附注 截至 2024 年 6 月 30 日
(除特别注明外, 金额单位均为人民币元)

I. 重要会计政策和会计估计

本公司为康宁医院(温州康宁精神康复医院)的控股公司, 成立于 1996 年。本公司主要从事精神科、内科、外科、妇产科、儿科、眼科、耳鼻喉科、口腔科、皮肤科、检验科、影像科、康复科、中医科、预防保健科、健康体检中心等医疗服务。本公司为康宁医院(温州康宁精神康复医院)的控股公司, 成立于 1996 年。本公司主要从事精神科、内科、外科、妇产科、儿科、眼科、耳鼻喉科、口腔科、皮肤科、检验科、影像科、康复科、中医科、预防保健科、健康体检中心等医疗服务。

2015 年 12 月 15 日, 本公司与康宁医院(温州康宁精神康复医院)签订了《股权转让协议》, 约定本公司受让康宁医院(温州康宁精神康复医院) 100% 的股权。该股权转让已于 2015 年 12 月 15 日完成工商变更登记手续, 本公司自该日起成为康宁医院(温州康宁精神康复医院)的控股股东。

本公司采用公允价值计量金融资产、金融负债、以公允价值计量的资产或负债以及公允价值计量的非金融资产。公允价值是指市场参与者在计量日发生的有序交易中, 出售一项资产所能收到的或者转移一项负债所需支付的价格。公允价值计量所使用的输入值分为三个层次, 即: 第一层次输入值是在计量日能够取得的相同资产或负债在活跃市场上未经调整的报价; 第二层次输入值是除第一层次输入值外相关资产或负债直接或间接可观察到的输入值; 第三层次输入值是相关资产或负债的不可观察输入值。

截至 2024 年 6 月 30 日, 本公司持有的金融资产公允价值为 20.09 万元, 其中: 以公允价值计量的金融资产为 20.09 万元, 以公允价值计量的金融负债为 0 元。



Notes to the Financial Statements

截至2024年6月30日

(A 资产负债表)

II. B 资产类科目

(I) Basis of preparation

本财务报表按照企业会计准则编制。A 资产类科目 B 资产类科目
 E 资产类科目 B 资产类科目。E 资产类科目 B 资产类科目
 A 资产类科目 B 资产类科目 E 资产类科目 A 资产类科目 B 资产类科目
 E 资产类科目。E 资产类科目 F₁ (资产类科目 B 资产类科目
 A 资产类科目 B 资产类科目 E 资产类科目), E 资产类科目
 C 资产类科目 I 资产类科目 D₁ 资产类科目 C 资产类科目 15
 G 资产类科目 F₁ 资产类科目 C 资产类科目 C 资产类科目
 G 资产类科目 E 资产类科目 H 资产类科目
 H 资产类科目 C 资产类科目

A 资产类科目 B 资产类科目 E 资产类科目 32 I 资产类科目 F₁ 资产类科目
 F₁ 资产类科目

G 资产类科目 B 资产类科目

Notes to the Financial Statements

For the period from January 1, 2024 to June 30, 2024
(All amounts are in RMB million unless otherwise specified)

II. Basis of preparation (Continued)

(II) Going concern

The Company has assessed its ability to continue as a going concern and has concluded that it is appropriate to prepare the financial statements on a going concern basis.

(III) Statement of compliance with the Accounting Standards for Business Enterprises

The Company has prepared its financial statements in accordance with the Accounting Standards for Business Enterprises (ASBE) issued by the Ministry of Finance of the People's Republic of China. The Company has also adopted the relevant accounting policies and estimates for the period from January 1, 2024 to June 30, 2024. The Company has also adopted the relevant accounting policies and estimates for the period from January 1, 2024 to June 30, 2024.

III. Tax

(I) Major tax categories and tax rates

Tax categories	Tax basis	Tax rate
Value-added tax (VAT)	On the net amount of taxable sales of goods and services, and on the net amount of taxable sales of intangible assets	3%, 6%, 13%
Corporate income tax	On the taxable income of the Company and its subsidiaries	7%
Stamp duty	On the taxable income of the Company and its subsidiaries	5%
Education surcharge	On the taxable income of the Company and its subsidiaries	15%, 20%, 25%
City maintenance tax	On the taxable income of the Company and its subsidiaries	
Taxpayer		Income tax rate
Wenzhou Kangning Hospital Co., Ltd.		15%
Wenzhou Kangning Hospital Co., Ltd. (subsidiary)		15%
Wenzhou Kangning Hospital Co., Ltd. (subsidiary)		20%

Notes to the Financial Statements

Ex 24 J 30, 2024

(A) (B)

III. γ (C γ $\bullet$)

(II) Preferential tax treatment

- [illegible]

Notes to the Financial Statements

English version is authoritative. In case of discrepancy, the Chinese version shall prevail.
(A) (B)

1. Balance sheet as at the end of the period

Unit: RMB million

As at the end of the period

31, 2023 (),

30, 2024 (),

30, 2024 (),

30, 2023 ().

(I) Cash at bank and on hand

Items	Balance as at the end of the period	B
C	315,188.51	371,623.69
C	367,196,561.26	416,980,298.98
	5,790,683.70	1,509,798.72
	373,302,433.47	418,861,721.39

(II) Financial assets held for trading

Items	Balance as at the end of the period	B
Financial assets held for trading	7,599,178.13	7,350,298.53
Financial assets held for trading	7,599,178.13	7,350,298.53
	7,599,178.13	7,350,298.53

(III) Notes receivable

Items	Balance as at the end of the period	B
Notes receivable	763,849.74	
	763,849.74	

Notes to the Financial Statements

截至2024年6月30日
(除特别说明外，金额单位均为人民币元)

1. 应收账款

(IV) Accounts receivable

1. 按账龄披露

	Balance as at the end of the period	B 账面余额
账龄		
1年以内	443,637,522.96	425,833,221.01
1-2年	42,631,127.19	6,696,709.84
2-3年	4,507,504.01	4,480,032.80
3年以上	10,140,966.30	7,780,009.57
合计	500,917,120.46	444,789,973.22
坏账准备	52,814,699.44	24,348,903.66
	448,102,421.02	420,441,069.56

2. 按坏账准备计提方法披露

Balance as at the end of the period					B				
Book balance		Provision for bad debts		Book value	B		B		B
Category	Amount	Proportion (%)	Amount	Proportion of provision (%)	Amount	Proportion (%)	Amount	Proportion (%)	
按单项计提坏账准备									
1. 单项金额重大并单项计提坏账准备的应收账款	28,701,127.14	5.73	24,270,288.56	84.56	4,430,838.58	19,507,030.88	4.39	12,854,582.28	65.90
2. 单项金额不重大但单项计提坏账准备的应收账款									
合计	28,701,127.14	5.73	24,270,288.56	84.56	4,430,838.58	19,507,030.88	4.39	12,854,582.28	65.90
按组合计提坏账准备									
1. 账龄组合									
2. 信用风险特征组合									
合计	472,215,993.32	94.27	28,544,410.88	6.04	443,671,582.44	425,282,942.34	95.61	11,494,321.38	2.70
合计	500,917,120.46	100.00	52,814,699.44		448,102,421.02	444,789,973.22	100.00	24,348,903.66	420,441,069.56

Notes to the Financial Statements

December 31, 2024
(Amount in RMB)

1. (Continued)

(IV) Accounts receivable (Continued)

2. A (Continued)

Balance as at the end of the period					B	
Item	Book balance	Provision for bad debts	Proportion of provision (%)	Reason for the provision	B	
•	28,701,127.14	24,270,288.56	84.56	EC	19,507,030.88	12,854,582.28
	28,701,127.14	24,270,288.56			19,507,030.88	12,854,582.28

•

Balance as at the end of the period			
Item	Accounts receivable	Provision for bad debts	Proportion of provision (%)
•	472,215,993.32	28,544,410.88	6.04
	472,215,993.32	28,544,410.88	

Notes to the Financial Statements

June 30, 2024
(Amount in thousands of RMB)

1. (Continued)

(IV) Accounts receivable (Continued)

3. Changes in the current period

Category	Changes in the current period				Balance as at the end of the period
	B	Provided for	Recovered or reversed	Written-back or written-off	
Accounts receivable					
1. Accounts receivable	12,854,582.28		-11,415,706.28		24,270,288.56
2. Accounts receivable	11,494,321.38	17,050,089.50			28,544,410.88
	24,348,903.66	17,050,089.50	-11,415,706.28		52,814,699.44

(V) Advances to suppliers

1. Balance as at the end of the period

Aging	Balance as at the end of the period		B	
	Amount	Proportion (%)	A	(%)
1. 1 year or less	2,326,232.07	98.28	9,048,941.18	92.05
2. 1-2 years			742,811.80	7.56
3. 2-3 years	7,919.67	0.33	6,000.00	0.06
4. 3 years or more	32,800.00	1.39	32,800.00	0.33
	2,366,951.74	100.00	9,830,552.98	100.00

Notes to the Financial Statements

English version is authoritative. In case of discrepancy, the Chinese version shall prevail.
(A) (B)

(C)

(VI) Other receivables

Items	Balance as at the end of the period	B
1	787,500.00	
	69,155,527.66	69,705,728.98
	69,943,027.66	69,705,728.98

1. 1
1

Items	Balance as at the end of the period	B
	787,500.00	
	787,500.00	

2. (1) D

Aging	Balance as at the end of the period	B
1 1	50,656,821.58	53,412,990.26
1 2	15,533,337.46	29,894,811.69
2 3	33,706,673.72	8,912,677.15
3 4	1,438,191.47	5,404,423.07
4 5	1,977,221.69	742,744.83
5	4,436,981.60	3,885,239.68
	107,749,227.52	102,252,886.68
	38,593,699.86	32,547,157.70
	69,155,527.66	69,705,728.98

Notes to the Financial Statements

For the period ending June 30, 2024
(All amounts in RMB unless otherwise specified)

1. Other receivables (Continued)

(VI) Other receivables (Continued)

2. Other receivables (Continued)

(2) Details of other receivables

Category	Balance as at the end of the period				B				
	Book balance		Provision for bad debts		B		B		B
	Amount	Proportion (%)	Amount	Proportion of provision (%)	Book value	Amount	Proportion (%)	Amount	
Accounts receivable	36,761,735.90	34.12	36,761,735.90	100.00	37,404,736.41	36.58	30,697,494.28	82.07	6,707,242.13
Prepaid expenses									
Other receivables									
H									
C	23,066,977.13	21.41	23,066,977.13	100.00	23,709,977.64	23.19	17,002,735.51	71.71	6,707,242.13
H									
C	10,204,311.69	9.47	10,204,311.69	100.00	10,204,311.69	9.98	10,204,311.69	100.00	
C (汪長勝)	3,490,447.08	3.24	3,490,447.08	100.00	3,490,447.08	3.41	3,490,447.08	100.00	
H									
C									
H									
C	70,987,491.62	65.88	1,831,963.96	2.58	69,155,527.66	64,848,150.27	63.42	1,849,663.42	2.85
H									
C	70,987,491.62	65.88	1,831,963.96	2.58	69,155,527.66	64,848,150.27	63.42	1,849,663.42	2.85
H									
C	107,749,227.52	100.00	38,593,699.86		69,155,527.66	102,252,886.68	100.00	32,547,157.70	69,705,728.98

Notes to the Financial Statements

English version is authoritative in case of discrepancy with the Chinese version.
(A) (B)

(C)

(VI) Other receivables (Continued)

2. (C)

(2) (C)

Name	Balance as at the end of the period			B	
	Book balance	Provision for bad debts	Proportion of provision (%)		
H				E	
H C . .	23,066,977.13	23,066,977.13	100.00	23,709,977.64	17,002,735.51
H					
W H				E	
W H	10,204,311.69	10,204,311.69	100.00	10,204,311.69	10,204,311.69
C (汪長勝)	3,490,447.08	3,490,447.08	100.00	3,490,447.08	3,490,447.08
	36,761,735.90	36,761,735.90		37,404,736.41	30,697,494.28

Name	Balance as at the end of the period		
	Other receivables	Provision for bad debts	Proportion of provision (%)
	70,987,491.62	1,831,963.96	2.58
	70,987,491.62	1,831,963.96	

Notes to the Financial Statements

Feb 30, 2024

(A) $\rightarrow$ (B) $\rightarrow$ (C)

I . 9 • 7 7 8 (C 7 •)

(VI) Other receivables (Continued)

2. ~~What~~ γ (C γ •)

(3) D γ $\gamma\gamma$ $\gamma\gamma\gamma$

[illegible]

Notes to the Financial Statements

English version is authoritative. In case of discrepancy, the Chinese version shall prevail.
(A) (B)

(C)

(VI) Other receivables (Continued)

2. (C)

(3) D (C)

C

	Stage I	Stage II	Stage III	
		Lifetime ECL (not credit impaired)	Lifetime ECL (credit impaired)	Total
Book balance	12-month ECL			
B				
	64,848,150.27		37,404,736.41	102,252,886.68
B				
A	6,139,341.35			6,139,341.35
D			643,000.51	643,000.51
B				
	70,987,491.62		36,761,735.90	107,749,227.52

Notes to the Financial Statements

For the period ending June 30, 2024
(All amounts are in RMB unless otherwise specified)

1. Other receivables (Continued)

(VI) Other receivables (Continued)

2. Other receivables (Continued)

(4) Changes in the current period

Category	B Balance at the end of the period	Changes in the current period				Balance as at the end of the period
		Provided for	Recovered or reversed	Written-back or written-off	Other changes	
Accounts receivable	30,697,494.28	6,064,241.62				36,761,735.90
Other receivables	1,849,663.42		17,428.98	270.48		1,831,963.96
	32,547,157.70	6,046,241.62	17,428.98	270.48		38,593,699.86

(5) Other receivables

	Book balance as at the end of the period	B Balance at the end of the period
D	22,840,821.05	22,266,761.49
E	25,289,000.00	19,150,000.00
I	1,583,692.95	4,818,862.51
A	23,134.70	51,045.33
A	51,845,560.25	52,887,698.31
A	2,000,000.00	
	4,167,018.57	3,078,519.04
	107,749,227.52	102,252,886.68

Ex 24 J 30, 2024

(A)  (B) 

		Balance as at the end of the period		B		
Category	Book balance	Provision for decline in the value of inventories/impairment provision for contract performance costs	Book value	B		B
	1,230,185.02		1,230,185.02	1,616,778.62		1,616,778.62
G	541,753.33		541,753.33	4,571,610.82		4,571,610.82
C	50,117,702.41		50,117,702.41	54,411,790.81		54,411,790.81
	51,889,640.76		51,889,640.76	60,600,180.25		60,600,180.25

Items	Balance as at the end of the period	B
1	2,006,813.22	205,753.33
2		4,368.35
3	1,046,974.56	647,898.71
	3,053,787.78	858,020.39

Balance as at the end of the period		B		D	
Item	Book balance	Provision for bad debts	Book value	B	D
Accounts receivable	14,000,000.00		14,000,000.00		
Allowance for doubtful accounts		14,000,000.00			14,000,000.00
	14,000,000.00	14,000,000.00	14,000,000.00		14,000,000.00

Notes to the Financial Statements

Unit: RMB million
(A) (B)

X. Long-term equity investments

Investees	Balance of the impairment provision as at the end of the previous year	Increase/decrease in the current period					Balance of the impairment provision as at the end of the period
		Investment profit/loss recognized under equity method	Other comprehensive income adjustment	Other equity changes	Cash dividends or profits declared and paid	Impairment provision	
A							
H A							
C	16,018,884.98	687,659.39					16,706,544.37
H C	56,841,432.86	-166,415.53					56,675,017.33
H H							
C	21,561,607.67	-393,224.24					21,168,383.43
H C							
C	22,287,534.75	712,327.54					22,999,862.29
C H							
H C	18,649,398.65	-31,479.31					18,617,919.34
F							
C	3,713,128.14	-330,039.89					5,393,088.25
	139,071,997.05	478,827.96					141,550,815.01

Notes to the Financial Statements

Wenzhou Kangning Hospital Co., Ltd. 30, 2024
(Amount in thousands of RMB)

1. Other non-current financial assets (Continued)

(XI) Other non-current financial assets

	Balance as at the end of the period	B 2024
1. Other non-current financial assets		
Financial assets measured at fair value through other comprehensive income	64,751,652.55	65,099,055.34
1.1. Other non-current financial assets measured at fair value through other comprehensive income	64,751,652.55	65,099,055.34
	64,751,652.55	65,099,055.34

(XII) Fixed assets

1. Fixed assets

Items	Balance as at the end of the period	B 2024
1. Fixed assets	782,127,103.00	794,856,342.94
D1. Fixed assets		
	782,127,103.00	794,856,342.94

Notes to the Financial Statements

December 30, 2024
(Amount in thousands of RMB)

1. (Continued)

(XII) Fixed assets (Continued)

2. Depreciation

	Buildings and structure	Medical equipment	Motor vehicles	Electronic and other equipment	Fixed assets leased under sale-and-leaseback finance leases	Total
1. Buildings and structure						
(1) Buildings and structure	870,189,179.09	80,978,235.73	13,585,774.73	62,896,115.93	101,426,794.17	1,129,076,099.65
(2) Buildings and structure	1,349,135.60	8,331,368.92	767,123.03	3,310,931.83		13,758,559.38
(3) Buildings and structure	1,349,135.60	8,331,368.92	767,123.03	3,310,931.83		13,758,559.38
(4) Buildings and structure		4,377,292.00		965,585.92		5,342,877.92
(5) Buildings and structure		4,377,292.00		965,585.92		5,342,877.92
(6) Buildings and structure	871,538,314.69	84,932,312.65	14,352,897.76	65,241,461.84	101,426,794.17	1,137,491,781.11
2. Medical equipment						
(1) Medical equipment	141,204,440.95	58,760,403.20	8,132,499.35	44,567,939.35	81,554,473.86	334,219,756.71
(2) Medical equipment	12,815,495.67	5,944,250.78	574,787.27	4,259,232.29	2,347,658.56	25,941,424.57
(3) Medical equipment	12,815,495.67	5,944,250.78	574,787.27	4,259,232.29	2,347,658.56	25,941,424.57
(4) Medical equipment		3,982,635.56		813,867.61		4,796,503.17
(5) Medical equipment		3,982,635.56		813,867.61		4,796,503.17
(6) Medical equipment	154,019,936.62	60,722,018.42	8,707,286.62	48,013,304.03	83,902,132.42	355,364,678.11
3. Motor vehicles						
(1) Motor vehicles						
(2) Motor vehicles						
(3) Motor vehicles						
(4) Motor vehicles						
4. Electronic and other equipment						
(1) Electronic and other equipment	717,518,378.07	24,210,294.23	5,645,611.14			

Notes to the Financial Statements

截至2024年6月30日
(除特别说明外，均以人民币元为单位)

1. 在建工程 (Construction in progress)

(XIII) Construction in progress

1. 在建工程	截至2024年6月30日			
	Balance as at the end of the period			B
	Book balance	Impairment provision	Carrying amount	B
Items				
C 在建工程	234,034,296.61		234,034,296.61	186,980,240.67
C 在建工程				186,980,240.67
	234,034,296.61		234,034,296.61	186,980,240.67
2. 固定资产	截至2024年6月30日			
	Balance as at the end of the period			B
	Book balance	Impairment provision	Carrying amount	B
Items				
H 固定资产	137,317,869.97		137,317,869.97	101,029,929.74
H 固定资产				
H 在建工程	89,526,711.76		89,526,711.76	85,174,600.41
H 在建工程				
H 在建工程	3,766,450.99		3,766,450.99	
H 在建工程	3,423,263.89		3,423,263.89	775,710.52
	234,034,296.61		234,034,296.61	186,980,240.67

Notes to the Financial Statements

截至 2024 年 6 月 30 日

(A 股) 人民币元

1. 资产负债表

(XIV) Right-of-use assets

Items	Buildings and structure	Total
1. 使用权资产		
(1) B	301,405,111.73	301,405,111.73
(2) I	70,408.22	70,408.22
	70,408.22	70,408.22
(3) D	1,131,585.84	1,131,585.84
	1,131,585.84	1,131,585.84
(4) B	300,343,934.11	300,343,934.11
2. A		
(1) B	112,350,605.05	112,350,605.05
(2) I	18,029,069.41	18,029,069.41
	18,029,069.41	18,029,069.41
(3) D	500,865.89	500,865.89
	500,865.89	500,865.89
(4) B	129,878,808.57	129,878,808.57
3. I		
(1) B		
(2) I		
(3) D		
(4) B		
4. C		
(1) C	170,465,125.54	170,465,125.54
(2) C	189,054,506.68	189,054,506.68

Notes to the Financial Statements

For the period ending June 30, 2024
(All amounts are in RMB unless otherwise specified)

1. (C)

(XV) Intangible assets

		Land use rights	Trademark rights	Software	Medical practice qualifications	Contractual rights to provide management services	Total
1. (1)B							
		154,962,176.05	3,061,637.13	16,215,218.87	216,837,000.00	32,400,000.00	423,476,032.05
(2)I		13,635.58		1,978,663.72			1,992,299.30
		13,635.58		1,978,663.72			1,992,299.30
(3)D							
(4)B							
		154,975,811.63	3,061,637.13	18,193,882.59	216,837,000.00	32,400,000.00	425,468,331.35
2. A							
(1)B							
		20,300,242.06	1,077,654.89	8,107,861.28	62,972,140.09	10,696,428.57	103,154,326.89
(2)I		1,560,910.96	163,620.15	1,319,911.39	10,529,799.87	864,285.71	14,438,528.08
		1,560,910.96	163,620.15	1,319,911.39	10,529,799.87	864,285.71	14,438,528.08
(3)D							
(4)B							
		21,861,153.02	1,241,275.04	9,427,772.67	73,501,939.96	11,560,714.28	117,592,854.97
3. I							
(1)B							
(2)I							
(3)D							
(4)B							
4. C							
(1)C		133,114,658.61	1,820,362.09	8,766,109.92	143,335,060.04	20,839,285.72	307,875,476.38
(2)C		134,661,933.99	1,983,982.24	8,107,357.59	153,864,859.91	21,703,571.43	320,321,705.16

Notes to the Financial Statements

June 30, 2024
(Amount in RMB)

(CNY)

(XVI) Goodwill

1. Goodwill

Name of the investees or events generating goodwill	B	Increase in the current period	Decrease in the current period	Balance as at the end of the period
		Arising from business combination	Disposal of goodwill impairment	
Wenzhou Kangning Hospital Co., Ltd.	9,271,800.00			9,271,800.00
Hangzhou Kangning Hospital Co., Ltd.	690,331.47			690,331.47
Guangzhou Kangning Hospital Co., Ltd.	1,549,022.38			1,549,022.38
Dongguan Kangning Hospital Co., Ltd.	7,784,850.00			7,784,850.00
Benzhou Kangning Hospital Co., Ltd.	22,987,331.04			22,987,331.04
Chengdu Kangning Hospital Co., Ltd.	151,048.40			151,048.40
Hangzhou Kangning Hospital Co., Ltd.	5,068,959.78			5,068,959.78
Chengdu Kangning Hospital Co., Ltd.	6,843,288.91			6,843,288.91
Chengdu Kangning Hospital Co., Ltd.	19,416,285.97			19,416,285.97
Chengdu Kangning Hospital Co., Ltd.	51,770,194.67			51,770,194.67
Hangzhou Kangning Hospital Co., Ltd.	1,272,643.00			1,272,643.00
Jiangsu Kangning Hospital Co., Ltd.	5,060,323.85			5,060,323.85
Chengdu Kangning Hospital Co., Ltd.	283,528.10			283,528.10
Dongguan Kangning Hospital Co., Ltd.	2,502,854.13			2,502,854.13
Chengdu Kangning Hospital Co., Ltd.	9,564,442.65			9,564,442.65
Chengdu Kangning Hospital Co., Ltd.	228,538.31			228,538.31
	144,445,442.66			144,445,442.66
Benzhou Kangning Hospital Co., Ltd.	22,987,331.04			22,987,331.04
Guangzhou Kangning Hospital Co., Ltd.	1,549,022.38			1,549,022.38
	24,536,353.42			24,536,353.42
Chengdu Kangning Hospital Co., Ltd.	119,909,089.24			119,909,089.24

Notes to the Financial Statements

English version
(A) (B)

(C)

(XVI) Goodwill (Continued)

2. The carrying amount of goodwill is as follows:

Unit: RMB'0,000

Name of goodwill asset groups or portfolio of asset groups	Composition and basis of asset groups or portfolio of asset groups	Carrying amount as at the end of the period	Consistent with the prior years or not
Wenzhou Kangning Hospital Co., Ltd.	A	1,342.46	
Hangzhou Kangning Hospital Co., Ltd.	A	1,645.65	
Gaozhou Kangning Hospital Co., Ltd.	A	1,074.50	
Hangzhou Kangning Hospital Co., Ltd.	A	771.11	
Benzhou Kangning Hospital Co., Ltd.	A	4,178.64	
Hangzhou Kangning Hospital Co., Ltd.	A	14.48	
Hangzhou Kangning Hospital Co., Ltd.	A	552.41	
Hangzhou Kangning Hospital Co., Ltd.	A	1,278.50	
Hangzhou Kangning Hospital Co., Ltd.	A	3,726.83	
Hangzhou Kangning Hospital Co., Ltd.	A	12,548.35	
Hangzhou Kangning Hospital Co., Ltd.	A	181.32	
Hangzhou Kangning Hospital Co., Ltd.	A	7,011.47	
Hangzhou Kangning Hospital Co., Ltd.	A	2,485.39	
Hangzhou Kangning Hospital Co., Ltd.	A	2,179.53	
Hangzhou Kangning Hospital Co., Ltd.	A	2,792.84	
Hangzhou Kangning Hospital Co., Ltd.	A	4.09	
		41,787.57	

Notes to the Financial Statements

June 30, 2024

(A) (B)

(C)

(XVII) Long-term prepaid expenses

Items	B	Increase in the current period	Amortisation in the current period	Balance as at the end of the period
	175,706,029.27	1,863,337.07	21,012,423.47	156,556,942.87
	178,292.93	38,000.00	41,641.68	174,651.25
	26,303.94		7,316.61	18,987.33
	175,910,626.14	1,901,337.07	21,061,381.76	156,750,581.45

(XVIII) Deferred tax assets and deferred tax liabilities

1. D

Items	Balance as at the end of the period		B	
	Deductible temporary differences	Deferred tax assets	D	D
	37,735,416.76	7,995,190.93	25,318,013.56	5,221,670.24
	36,307,991.72	9,076,997.93	3,073,067.80	3,073,067.80
	94,761,661.96	18,358,697.14	126,627,704.89	26,623,506.01
	178,203,515.38	44,007,128.21	181,046,756.88	45,261,689.23
	55,456,176.01	8,308,050.85	54,688,502.33	8,203,275.35
	402,464,761.83	87,746,065.06	390,754,045.46	88,383,208.63

E 7 J 30, 2024
 (A 7 B 7)

Notes to the Financial Statements

December 31, 2024
(Amount in thousands of RMB)

(XX) Assets with restricted ownership or right-of-use

Items	As at the end of the period		Types for restriction	Case for restriction	A		
	Book balance	Carrying amount			B	C	C
C				Bank acceptance deposit			B
	150,009.00	150,009.00	Guarantee		772,510.54	772,510.54	
	5,000,000.00	5,000,000.00	Guarantee	Performance bond	12,000,000.00	12,000,000.00	
				Foreign Exchange Control Account	1,361,750.73	1,361,750.73	
	1,363,135.53	1,363,135.53	Freezing		2,120.75	2,120.75	
					2,000.00	2,000.00	
	208,244,700.00	208,244,700.00	Pledge	Pledged loans	208,244,700.00	208,244,700.00	
				Sale and leaseback	101,426,794.17	19,872,320.31	
	104,902,010.82	104,902,010.82	Mortgage	Secured borrowings	161,856,152.45	156,403,844.80	
	215,173,758.25	215,173,758.25	Mortgage	Secured borrowings	59,523,538.00	52,511,079.33	
	26,041,873.00	26,041,873.00	Mortgage				
	240,799,717.53	240,799,717.53			281,904,499.27	274,892,040.60	

(XXI) Short-term borrowings

Items	Balance as at the end of the period	B
	111,000,000.00	125,000,000.00
		2,001,700.00
	111,000,000.00	127,001,700.00

Notes to the Financial Statements

附注 截至 2024 年 6 月 30 日
(除特别说明外, 货币单位均为人民币元)

1. 重要会计政策及会计估计 (续)

(XXII) Financial liabilities held for trading

Items	Balance as at the end of the period	B 人民币元
交易性金融资产	12,400,000.00	12,400,000.00

(XXIII) Accounts payable

Items	Balance as at the end of the period	B 人民币元

Notes to the Financial Statements

For the period from January 1 to June 30, 2024
(All figures are in thousands of RMB)

I. General information (C)

(XXVI)

Notes to the Financial Statements

截至2024年6月30日
(除特别说明外，所有金额均以人民币元为单位)

续表

(XXVI) Employee benefits payable (Continued)

3. 应付职工薪酬

Items	B 元	Increase in the current period	Decrease in the current period	Balance as at the end of the period
	元			
B 应付职工薪酬	4,118,499.45	17,853,475.62	19,109,187.58	2,862,787.49
- 应付职工薪酬	141,199.04	593,688.95	648,098.81	86,789.18
	4,259,698.49	18,447,164.57	19,757,286.39	2,949,576.67

应付职工薪酬包括：应付工资、应付奖金、应付津贴和补贴、应付福利费、应付社会保险费、应付住房公积金、应付工会经费和职工教育经费等。

(XXVII) Taxes payable

Items	Balance as at the end of the period	B 元
		元
- 应交税费 (A)	2,694,016.67	3,056,261.74
E 应交税费	22,926,288.67	30,600,774.99
I 应交税费	1,720,787.95	1,148,089.23
C 应交税费	104,506.51	134,739.29
应付职工薪酬	3,012,925.99	2,960,159.04
E 应交税费	74,789.97	96,590.18
	305,640.50	523,438.18
	13,843.13	31,053.22
E 应交税费	2,094.00	1,869.00
应交税费 F	552.42	771.60
	30,855,445.81	38,553,746.47

Notes to the Financial Statements

English version is authoritative. In case of discrepancy, the Chinese version shall prevail.
(A) (B) (C)

1. (C)

(XXVIII) Other payables

Items	Balance as at the end of the period	B
1. Other payables		35,313.43
2. Other payables	2,370,000.00	624,000.00
	66,117,137.05	149,611,261.72
	68,487,137.05	150,270,575.15

1. Other payables

Items	Balance as at the end of the period	B
1. Other payables		35,313.43
		35,313.43

2. Other payables

Items	Balance as at the end of the period	B
2. Other payables	2,370,000.00	624,000.00
	2,370,000.00	624,000.00

Notes to the Financial Statements

English version is authoritative. In case of discrepancy, the Chinese version shall prevail.
(A) (B)

(C)

(XXVIII) Other payables (Continued)

3.

Items	Balance as at the end of the period	B
1	17,785,659.46	62,637,634.31
2	1,313,457.77	1,313,457.77
3	1,740,116.45	6,766,360.73
D	1,237,034.24	1,663,762.95
C	29,986,754.10	38,542,529.94
4	3,677,029.66	9,845,641.28
A	8,254,225.35	28,481,495.22
	2,122,860.02	360,379.52
	66,117,137.05	149,611,261.72

(XXIX) Non-current liabilities due within one year

Items	Balance as at the end of the period	B
1	44,136,233.34	180,020,000.00
2	41,370,743.00	41,747,868.00
3	22,779,404.91	28,643,888.99
	108,286,381.25	250,411,756.99

Notes to the Financial Statements

December 31, 2024
(Amount in RMB)

1. Other current liabilities

(XXX) Other current liabilities

Items	Balance as at the end of the period	B
Accounts payable	5,575.47	
Other current liabilities	563,849.74	
	569,425.21	

(XXXI) Long-term borrowings

Items	Balance as at the end of the period	B
Long-term borrowings	89,166,233.34	212,842,127.25
Guaranteed principal	306,620,000.00	252,010,000.00
Guaranteed interest	416,574,669.65	272,887,087.44
Other long-term borrowings	44,136,233.34	180,020,000.00
	768,224,669.65	557,719,214.69

(XXXII) Lease liabilities

Items	Balance as at the end of the period	B
Lease liabilities	158,912,952.10	163,239,532.76
	158,912,952.10	163,239,532.76

Notes to the Financial Statements

English version is authoritative. In case of discrepancy, the Chinese version shall prevail.
(A) (B)

(C)

(XXXIII) Long-term accounts payable

Items	Balance as at the end of the period	B
	64,227,913.88	61,351,340.53
	64,227,913.88	61,351,340.53

Items	Balance as at the end of the period	B
F	105,598,656.88	103,099,208.53
I	15,254,200.16	15,109,210.13
	41,370,743.00	41,747,868.00
	64,227,913.88	61,351,340.53

(XXXIV) Deferred income

Items	B	Increase in the current period	Decrease in the current period	Balance as at the end of the period
G	8,734,099.00		151,896.00	8,582,203.00
	8,734,099.00		151,896.00	8,582,203.00

(XXXV) Share capital

Increase (+) decrease (-) in the current period							Balance as at the end of the period
Items	B	Issuance of new shares	Bonus issue	conversion from reserves	others	Subtotal	
	74,600,300.00						74,600,300.00

Notes to the Financial Statements

截至2024年6月30日
(除特别说明外，金额单位均为人民币元)

1. 资本公积

(XXXVI) Capital surplus

Items	B 元	Increase in the current period	Decrease in the current period	Balance as at the end of the period
资本溢价	781,037,804.26		12,709,794.63	768,328,009.63
其他资本公积	44,857,374.20	767,673.68		45,625,047.88
合计	26,800,423.23			26,800,423.23
	852,695,601.69	767,673.68	12,709,794.63	840,753,480.74

(XXXVII) Treasury stock

Items	B 元	Increase in the current period	Decrease in the current period	Balance as at the end of the period
库存股	12,587,011.74		9,440,179.03	3,146,832.71
合计	12,587,011.74		9,440,179.03	3,146,832.71

(XXXVIII) Surplus reserve

Items	B 元	Increase in the current period	Decrease in the current period	Balance as at the end of the period
盈余公积	38,399,577.13			38,399,577.13
合计	38,399,577.13			38,399,577.13

Notes to the Financial Statements

For the period ending June 30, 2024
(Amount in thousands of RMB)

1. (C)

(XXXIX) Retained earnings

Items	Amount for the current period	Amount at the beginning of the period
Retained earnings at the beginning of the period	311,956,229.16	233,506,534.43
Net profit for the period	311,956,229.16	233,506,534.43
Less: Dividends paid	50,723,744.20	85,947,806.64
Less: Other distributions		
Less: Other distributions		
Less: Other distributions		
Less: Other distributions	22,380,090.00	7,498,111.91
Retained earnings at the end of the period	340,299,883.36	311,956,229.16

(XL) Revenue and cost of sales

Items	Amount for the current period		Amount at the beginning of the period	
	Revenue	Cost	Revenue	Cost
Operating revenue	765,636,198.08	555,217,793.42	728,692,633.43	547,491,901.17
Operating cost	63,321,355.63	47,582,667.69	49,232,530.41	28,898,694.59
	828,957,553.71	602,800,461.11	777,925,163.84	576,390,595.76

Notes to the Financial Statements

For the period ending June 30, 2024
(All amounts are in RMB unless otherwise specified)

1. Revenue and cost of sales (Continued)

(XL) Revenue and cost of sales (Continued)

1. A (C)
B :

Items	Amount for the current period	A (C)
Revenue	765,636,198.08	728,692,633.43
Cost of sales	765,636,198.08	728,692,633.43
Net revenue	63,321,355.63	49,232,530.41
Cost of sales	41,715,643.36	28,881,807.57
Net cost of sales	7,958,001.19	1,485,148.50
Net revenue	297,619.53	2,857,971.77
Net cost of sales	13,350,091.55	16,007,602.57
	828,957,553.71	777,925,163.84

2. D (C)

Items	Time to fulfill performance obligations	Major payment terms	Nature of the goods that the Company promises to transfer	Do we take the major responsibility	Expected amounts that the Company has undertaken to return to customers	Types of quality assurance provided by the Company and associated obligations
Revenue	A	B ₁	D ₁			
Cost of sales						

Notes to the Financial Statements

Wen Zhou Kang Ning Hospital Co., Ltd. 30, 2024

(A) (B) (C)

(C)

(XLI) Taxes and charges

Items	Amount for the current period	Amount for the previous period
Value added tax	4,886,926.23	1,704,919.27
City maintenance tax	460,954.07	398,619.06
Education surcharge	331,720.92	284,861.86
Deed tax	445,099.29	244,228.99
Land use tax	130,348.60	139,457.81
Other taxes	13,249.84	11,774.66
	6,268,298.95	2,783,861.65

(XLII) Selling and distribution expenses

Items	Amount for the current period	Amount for the previous period
Advertising and promotion	5,264,561.40	4,571,354.43
Deportation	99,249.43	96,371.80
Advertising and promotion	21,787.27	22,513.69
Advertising and promotion	155,095.54	155,131.68
Entertainment	435,531.57	316,393.31
Travel	316,961.17	180,167.93
Transportation	179,730.55	167,234.65
Other		10,478.18
Advertising and promotion	219,294.83	235,841.00
Advertising and promotion	2,388,776.86	2,020,072.51
Advertising and promotion	139,038.00	25,268.40
Advertising and promotion	29,239.82	27,782.42
	9,249,266.44	7,828,610.00

Notes to the Financial Statements

For the period ending June 30, 2024
(All amounts are in RMB unless otherwise specified)

1. General and administrative expenses

(XIII) General and administrative expenses

Items	Amount for the current period	Amount for the corresponding period of the previous year
Salaries and wages	63,615,210.18	55,921,762.58
Debt interest	7,553,031.91	6,990,089.75
Administrative fees	1,874,457.13	1,800,111.04
Administrative expenses	4,527,100.72	4,684,159.80
Interest on bank deposits	963,471.75	1,039,347.77
Interest on bank loans	1,323,759.68	1,386,037.88
Interest on other financial assets	767,673.68	
Interest on other financial liabilities	2,276,602.65	1,700,201.12
Interest on other financial instruments	2,198,731.91	2,070,528.66
Interest on other financial instruments	351,396.86	717,753.37
Interest on other financial instruments	2,919,344.90	1,676,255.06
Interest on other financial instruments	1,024,421.20	1,263,793.76
Interest on other financial instruments	1,308,692.84	1,582,961.78
Interest on other financial instruments	1,815,859.33	14,377,209.14
Interest on other financial instruments	2,226,500.13	
Interest on other financial instruments	5,421,178.66	3,248,248.19
Interest on other financial instruments	2,803,324.36	2,599,553.04
Interest on other financial instruments	3,300,625.81	866,013.82
	106,271,383.70	101,924,026.76

(XIV) Research and development expenses

Items	Amount for the current period	Amount for the corresponding period of the previous year
Salaries and wages	17,015,841.55	13,998,896.69
Debt interest	313,121.72	191,563.81
Interest on bank deposits	23,806.46	92,076.48
Interest on bank loans	1,279.22	1,369.72
Interest on other financial assets	7,292.41	388,988.66
Interest on other financial liabilities	7,536.00	
Interest on other financial instruments	219,198.79	285,100.27
	17,588,076.15	14,957,995.63

Notes to the Financial Statements

Enacted on June 30, 2024

(A) (B) (C)

(C) (A) (B)

(XLV) Financial expenses

Items	Amount for the current period	Amount for the previous period
Interest expense	23,323,466.98	19,182,137.46
Interest expense on financial assets	5,245,075.86	5,058,106.16
Interest expense on financial liabilities	2,686,209.46	2,704,831.09
Interest expense on financial assets	99,244.67	-13,070.04
Interest expense on financial liabilities	3,728,948.96	3,695,397.63
	24,465,451.15	20,159,633.96

(XLVI) Other income

Items	Amount for the current period	Amount for the previous period
Government subsidies	5,386,176.18	5,600,421.10
Government subsidies	13,945.83	200,405.44
Government subsidies	188,141.27	21,668.61
	5,588,263.28	5,822,495.15

(XLVII) Investment income

Items	Amount for the current period	Amount for the previous period
Investment income	478,827.96	-157,522.45
Investment income	1,201,371.61	-38,203.48
	1,680,199.57	-195,725.93

Notes to the Financial Statements

For the period ending June 30, 2024
(Amount in thousands of RMB)

1. (Continued)

(XLVIII) Gain from change in fair value

Source of gains from changes in fair value	Amount for the current period	Amount for the prior period
Fair value change of financial assets	248,879.60	
Fair value change of financial liabilities	-347,402.79	
	-98,523.19	

(XLIX) Credit impairment losses

Items	Amount for the current period	Amount for the prior period
Impairment loss on financial assets	462,548.63	-3,047,374.71
Reversal of impairment loss on financial assets	-6,046,812.64	37,447.94
	-5,584,264.01	-3,009,926.77

(L) Gain from disposal of assets

Items	Amount for the current period	Amount for the prior period
Gain from disposal of non-current assets		
Gain from disposal of property, plant and equipment	-75,116.21	-75,116.21
Gain from disposal of investment properties	-75,116.21	-75,116.21
Gain from disposal of intangible assets	130.80	130.80
	-74,985.41	-74,985.41

Notes to the Financial Statements

For the period ending June 30, 2024
(All amounts are in RMB unless otherwise specified)

1. Income tax expenses

(LIII) Income tax expenses

1. Income tax expenses

Items	Amount for the current period	Amount for the prior period
Current income tax	19,082,552.41	23,358,206.57
Deferred income tax	-2,566,409.06	-11,880,326.50
	16,516,143.35	11,477,880.07

2. Income tax expenses

Items	Amount for the current period
Income tax	61,512,576.64
Income tax	12,647,013.90
Income tax	474,180.04
Income tax	-769,492.74
Income tax	817,638.14
Income tax	-4,610,218.14
Income tax	9,615,739.59
Income tax	-3,065,849.16
Income tax	1,407,131.72
Income tax	16,516,143.35

Notes to the Financial Statements

For the period from January 1 to June 30, 2024
(Amount in thousands of RMB)

1. Earnings per share (C)

(LIV) Earnings per share

1. Basic earnings per share

Basic earnings per share		
Basic earnings per share is calculated by dividing the profit attributable to common shareholders by the weighted average number of shares outstanding during the period.		
The weighted average number of shares outstanding during the period is calculated as follows:		
Items	Amount for the current period	Amount for the corresponding period of last year
Weighted average number of shares outstanding during the period	50,723,744.20	43,750,057.46
Weighted average number of shares outstanding during the period	74,600,300.00	74,600,300.00
Basic earnings per share	0.68	0.59
Weighted average number of shares outstanding during the period	0.68	0.59
Weighted average number of shares outstanding during the period		

2. Diluted earnings per share

Diluted earnings per share is calculated by dividing the profit attributable to common shareholders by the weighted average number of shares outstanding during the period, including the weighted average number of shares that would be outstanding if all dilutive potential shares were exercised.		
The weighted average number of shares outstanding during the period is calculated as follows:		
Items	Amount for the current period	Amount for the corresponding period of last year
Weighted average number of shares outstanding during the period	50,723,744.20	43,750,057.46
Weighted average number of shares outstanding during the period	74,600,300.00	74,600,300.00
Diluted earnings per share	0.68	0.59
Weighted average number of shares outstanding during the period	0.68	0.59
Weighted average number of shares outstanding during the period		

operat575 -1.556 Td (Net profi996,433.29)Tt i01.496 -111e,535,983.61 Cre50,057.46

Notes to the Financial Statements

E 30, 2024
(A B)

(C)

(LV) Supplementary information to the cash flow statement

1.		Amount for the	A
	Supplementary information	current period	
1.			
		44,996,433.29	43,750,057.46
A : C	057.466843,7-3 7643,750,057.466843,750,057.46A,344.1643,7-3lem76		

[illegible]

Notes to the Financial Statements

English version is the final version
(Chinese version is the final version)

Name of subsidiary	Disposal price at the date of loss of control	Disposal at the date of loss of control	Percentage of disposals at the date of loss of control (%)	Basis for determining the date of loss of control	Difference between the consideration for disposal and the share of net assets of the subsidiary at the level of the relevant consolidated financial statements in which the disposed investments presented	Carrying amount of remaining equity at the level of the relevant consolidated financial statements in which on the date of loss of control	Fair value of remaining equity at the level of the relevant consolidated financial statements in which on the date of loss of control	Gain or loss on fair value remeasurement of remaining equity interests	Determination method and major assumptions of the fair value of remaining equity at the level of the relevant consolidated financial income relating to the equity investment in the former subsidiary
1. Wenzhou Kangning Hospital Co., Ltd. (温州肯己健康科技有限公司)	432,733.42	55.00	2024.1.1	-155,627.85					

(II) Changes in the scope of consolidation due to other reasons

1. Wenzhou Kangning Hospital Co., Ltd. (温州肯己健康科技有限公司)
2. Wenzhou Kangning Hospital Co., Ltd. (温州肯己健康科技有限公司)
3. Wenzhou Kangning Hospital Co., Ltd. (温州肯己健康科技有限公司)

Notes to the Financial Statements

截至2024年6月30日
(除特别说明外，货币单位均为人民币元)

一、 重要会计政策及会计估计
(I) 重要会计政策

1. 重要会计政策

Name of Subsidiary	Type of legal entity	Registered capital (RMB'0,000)	Major business location	Place of registration	Nature of business	Shareholding (%)		Method of acquisition
						Direct	Indirect	
温州康宁医院有限公司	C	20,000.00	温州	温州	H	100.00		全资收购
温州康宁医院有限公司	C	600.00	温州	温州	医疗服务		100.00	全资收购
温州康宁医院有限公司	C	6,000.00			医疗服务		100.00	全资收购
温州康宁医院有限公司	C	3,000.00			医疗服务		60.00	全资收购
温州康宁医院有限公司	C	1,000.00	温州	温州	医疗服务		51.00	全资收购
温州康宁医院有限公司	C	3,000.00	温州	温州	H		100.00	全资收购
温州康宁医院有限公司	C	1,000.00	温州	温州	医疗服务		51.00	全资收购
H 温州康宁医院有限公司	C	100.00	H	H	医疗服务		100.00	全资收购
温州康宁医院有限公司	C	500.00			医疗服务		100.00	全资收购
温州康宁医院有限公司	C	1,000.00	H	H	医疗服务		100.00	全资收购
温州康宁医院有限公司	C	1,000.00			医疗服务		100.00	全资收购
温州康宁医院有限公司	C	1,000.00	温州	温州	医疗服务		85.65	全资收购
H 温州康宁医院有限公司	C	3,000.00	H	H	医疗服务		51.00	全资收购
G 温州康宁医院有限公司	C	1,000.00	G	G	医疗服务		90.00	全资收购
温州康宁医院有限公司	C	753.00	温州	温州	医疗服务		68.80	全资收购
B 温州康宁医院有限公司	C	4,653.67	B	B	医疗服务		67.77	全资收购
温州康宁医院有限公司	C	50.00			医疗服务		100.00	全资收购
H 温州康宁医院有限公司	C	1,000.00	H	H	医疗服务		95.00	全资收购

Notes to the Financial Statements

English version is the original version. In case of inconsistency, the Chinese version shall prevail.
(All amounts are in RMB'0,000 unless otherwise specified.)

Name of Subsidiary	Type of legal entity	Registered capital (RMB'0,000)	Major business location	Place of registration	Nature of business	Shareholding (%)		Method of acquisition
						Direct	Indirect	
Wenzhou Kangning Hospital Co., Ltd.	C	2,040.82	H	H	Medical services		98.00	Investment
Wenzhou Kangning Hospital Co., Ltd. Dalian Branch	C	50.00			Medical services		100.00	Investment
Wenzhou Kangning Hospital Co., Ltd. Hangzhou Branch	C	500.00			Medical services		100.00	Investment
Wenzhou Kangning Hospital Co., Ltd. Dalian Branch	C	1,000.00			Medical services		80.00	Investment
Wenzhou Kangning Hospital Co., Ltd. Hangzhou Branch	C	2,200.00	C	C	Medical services		64.55	Investment
Wenzhou Kangning Hospital Co., Ltd. Hangzhou Branch	C	500.00	H	H	Medical services		100.00	Investment
Wenzhou Kangning Hospital Co., Ltd. Hangzhou Branch	C	100.00	H	H	Medical services		100.00	Investment
Wenzhou Kangning Hospital Co., Ltd. Hangzhou Branch	C	5,000.00			Medical services		100.00	Investment
Wenzhou Kangning Hospital Co., Ltd. Hangzhou Branch	C	6,000.00			Medical services		55.00	Investment
Wenzhou Kangning Hospital Co., Ltd. Hangzhou Branch								

A  B  C  D  E  F  G  H  I  100%.

Notes to the Financial Statements

December 31, 2024
(Amount in RMB)

1. Interests in subsidiaries (Continued)

2. Summary of financial data

Name of Subsidiary	Shareholding percentage of non-controlling shareholder	Current profits or losses attributable to non-controlling shareholders	Current dividends distributed to non-controlling shareholders	Closing balance of interest of non-controlling shareholders
Hong Kong Kangning Hospital Co., Ltd.	40.00%	44,686.00		30,411,626.36
Hangzhou Kangning Hospital Co., Ltd.	45.00%	-1,622,191.24		16,064,103.54

3. Balance sheet of subsidiaries

Name of Subsidiary	Balance as at the end of the period						B					
	Current assets	Non-current assets	Total assets	Current liabilities	Non-current liabilities	Total liabilities	Current assets	Non-current assets	Total assets	Current liabilities	Non-current liabilities	Total liabilities
Hangzhou Kangning Hospital Co., Ltd.	8,793,123.17	162,275,430.25	171,068,553.42	39,487.47	95,000,000.00	95,039,487.47	12,771,926.28	126,317,515.02	139,089,441.30	48,340.35	75,123,750.00	75,172,090.35
Hangzhou Kangning Hospital Co., Ltd.	8,951,720.53	70,164,028.21	79,115,748.74	14,151,720.45	28,010,857.21	42,162,577.66	13,868,975.32	71,012,513.90	84,881,489.22	15,643,448.52	28,680,000.20	44,323,448.72

Name of Subsidiary	Amount for the current period				A			
	Revenue	Net profit	Total comprehensive income	Cash flows from operating activities	Revenue	Net profit	Total comprehensive income	Cash flows from operating activities
Hangzhou Kangning Hospital Co., Ltd.		111,715.00	111,715.00	7,479,658.56	-1,000,974.74	-1,000,974.74	-3,869,458.16	
Hangzhou Kangning Hospital Co., Ltd.	9,111,507.81	-3,604,869.42	-3,604,869.42	-2,290,097.91	16,050,977.70	-2,852,161.57	-2,852,161.57	-8,603,908.46

Notes to the Financial Statements

English version is authoritative in case of discrepancy with the Chinese version.
(A) (B)

I. (C)

(II) Transactions that cause changes in the share of owners' equity in subsidiaries that do not result in loss of control

1. E
I F 2024, B
H C, C
B A I B0.3 B1
B15,300,000.00.
B H C B46,536,700.00,
C 51% 67.77%.

A C
B3,375,411.44,
()

(III) Interests in joint arrangements or associates

1.

Name of joint venture or associate	Major business location	Place of registration	Nature of business	Shareholding (%)		Accounting method for investment in joint ventures or associates	Whether strategic to the Company's activities or not
				Direct	Indirect		
H				45.00			
C					30.00		
C C							

Notes to the Financial Statements

Ex 24 J 30, 2024

(A)  (B) 

1. $\int_{\mathbb{R}^n} f(x) dx = \int_{\mathbb{R}^n} f(x) dx$ (C. 1.1)

(III) Interests in joint arrangements or associates *(Continued)*

2. $\frac{1}{\sqrt{2}} \begin{pmatrix} 1 & -1 \\ 1 & 1 \end{pmatrix}$

[illegible]

Notes to the Financial Statements

Encompassing the period from January 1, 2024, to June 30, 2024

(A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) (R) (S) (T) (U) (V) (W) (X) (Y) (Z) (AA) (AB) (AC) (AD) (AE) (AF) (AG) (AH) (AI) (AJ) (AK) (AL) (AM) (AN) (AO) (AP) (AQ) (AR) (AS) (AT) (AU) (AV) (AW) (AX) (AY) (AZ) (BA) (BB) (BC) (BD) (BE) (BF) (BG) (BH) (BI) (BJ) (BK) (BL) (BM) (BN) (BO) (BP) (BQ) (BR) (BS) (BT) (BU) (BV) (BW) (BX) (BY) (BZ) (CA) (CB) (CC) (CD) (CE) (CF) (CG) (CH) (CI) (CJ) (CK) (CL) (CM) (CN) (CO) (CP) (CQ) (CR) (CS) (CT) (CU) (CV) (CW) (CX) (CY) (CZ) (DA) (DB) (DC) (DD) (DE) (DF) (DG) (DH) (DI) (DJ) (DK) (DL) (DM) (DN) (DO) (DP) (DQ) (DR) (DS) (DT) (DU) (DV) (DW) (DX) (DY) (DZ) (EA) (EB) (EC) (ED) (EE) (EF) (EG) (EH) (EI) (EJ) (EK) (EL) (EM) (EN) (EO) (EP) (EQ) (ER) (ES) (ET) (EU) (EV) (EW) (EX) (EY) (EZ) (FA) (FB) (FC) (FD) (FE) (FF) (FG) (FH) (FI) (FJ) (FK) (FL) (FM) (FN) (FO) (FP) (FQ) (FR) (FS) (FT) (FU) (FV) (FW) (FX) (FY) (FZ) (GA) (GB) (GC) (GD) (GE) (GF) (GG) (GH) (GI) (GJ) (GK) (GL) (GM) (GN) (GO) (GP) (GQ) (GR) (GS) (GT) (GU) (GV) (GW) (GX) (GY) (GZ) (HA) (HB) (HC) (HD) (HE) (HF) (HG) (HH) (HI) (HJ) (HK) (HL) (HM) (HN) (HO) (HP) (HQ) (HR) (HS) (HT) (HU) (HV) (HW) (HX) (HY) (HZ) (IA) (IB) (IC) (ID) (IE) (IF) (IG) (IH) (II) (IJ) (IK) (IL) (IM) (IN) (IO) (IP) (IQ) (IR) (IS) (IT) (IU) (IV) (IW) (IX) (IY) (IZ) (JA) (JB) (JC) (JD) (JE) (JF) (JG) (JH) (JI) (JJ) (JK) (JL) (JM) (JN) (JO) (JP) (JQ) (JR) (JS) (JT) (JU) (JV) (JW) (JX) (JY) (JZ) (KA) (KB) (KC) (KD) (KE) (KF) (KG) (KH) (KI) (KJ) (KK) (KL) (KM) (KN) (KO) (KP) (KQ) (KR) (KS) (KT) (KU) (KV) (KW) (KX) (KY) (KZ) (LA) (LB) (LC) (LD) (LE) (LF) (LG) (LH) (LI) (LJ) (LK) (LL) (LM) (LN) (LO) (LP) (LQ) (LR) (LS) (LT) (LU) (LV) (LW) (LX) (LY) (LZ) (MA) (MB) (MC) (MD) (ME) (MF) (MG) (MH) (MI) (MJ) (MK) (ML) (MM) (MN) (MO) (MP) (MQ) (MR) (MS) (MT) (MU) (MV) (MW) (MX) (MY) (MZ) (NA) (NB) (NC) (ND) (NE) (NF) (NG) (NH) (NI) (NJ) (NK) (NL) (NM) (NN) (NO) (NP) (NQ) (NR) (NS) (NT) (NU) (NV) (NW) (NX) (NY) (NZ) (OA) (OB) (OC) (OD) (OE) (OF) (OG) (OH) (OI) (OJ) (OK) (OL) (OM) (ON) (OO) (OP) (OQ) (OR) (OS) (OT) (OU) (OV) (OW) (OX) (OY) (OZ) (PA) (PB) (PC) (PD) (PE) (PF) (PG) (PH) (PI) (PJ) (PK) (PL) (PM) (PN) (PO) (PP) (PQ) (PR) (PS) (PT) (PU) (PV) (PW) (PX) (PY) (PZ) (QA) (QB) (QC) (QD) (QE) (QF) (QG) (QH) (QI) (QJ) (QK) (QL) (QM) (QN) (QO) (QP) (QQ) (QR) (QS) (QT) (QU) (QV) (QW) (QX) (QY) (QZ) (RA) (RB) (RC) (RD) (RE) (RF) (RG) (RH) (RI) (RJ) (RK) (RL) (RM) (RN) (RO) (RP) (RQ) (RR) (RS) (RT) (RU) (RV) (RW) (RX) (RY) (RZ) (SA) (SB) (SC) (SD) (SE) (SF) (SG) (SH) (SI) (SJ) (SK) (SL) (SM) (SN) (SO) (SP) (SQ) (SR) (SS) (ST) (SU) (SV) (SW) (SX) (SY) (SZ) (TA) (TB) (TC) (TD) (TE) (TF) (TG) (TH) (TI) (TJ) (TK) (TL) (TM) (TN) (TO) (TP) (TQ) (TR) (TS) (TT) (TU) (TV) (TW) (TX) (TY) (TZ) (UA) (UB) (UC) (UD) (UE) (UF) (UG) (UH) (UI) (UJ) (UK) (UL) (UM) (UN) (UO) (UP) (UQ) (UR) (US) (UT) (UU) (UV) (UW) (UX) (UY) (UZ) (VA) (VB) (VC) (VD) (VE) (VF) (VG) (VH) (VI) (VJ) (VK) (VL) (VM) (VN) (VO) (VP) (VQ) (VR) (VS) (VT) (VU) (VV) (VW) (VX) (VY) (VZ) (WA) (WB) (WC) (WD) (WE) (WF) (WG) (WH) (WI) (WJ) (WK) (WL) (WM) (WN) (WO) (WP) (WQ) (WR) (WS) (WT) (WU) (WV) (WW) (WX) (WY) (WZ) (XA) (XB) (XC) (XD) (XE) (XF) (XG) (XH) (XI) (XJ) (XK) (XL) (XM) (XN) (XO) (XP) (XQ) (XR) (XS) (XT) (XU) (XV) (XW) (XX) (XY) (XZ) (YA) (YB) (YC) (YD) (YE) (YF) (YG) (YH) (YI) (YJ) (YK) (YL) (YM) (YN) (YO) (YP) (YQ) (YR) (YS) (YT) (YU) (YV) (YW) (YX) (YZ) (ZA) (ZB) (ZC) (ZD) (ZE) (ZF) (ZG) (ZH) (ZI) (ZJ) (ZK) (ZL) (ZM) (ZN) (ZO) (ZP) (ZQ) (ZR) (ZS) (ZT) (ZU) (ZV) (ZW) (ZX) (ZY) (ZZ)

II. Various risks associated with financial instruments

(I) Various risks associated with financial instruments

The Company's financial instruments are primarily cash, accounts receivable, accounts payable, and other financial assets and liabilities. The Company's financial instruments are subject to various risks, including credit risk, liquidity risk, and market risk. The Company has established a risk management system to identify, measure, and manage these risks.

The Company's financial instruments are primarily cash, accounts receivable, accounts payable, and other financial assets and liabilities. The Company's financial instruments are subject to various risks, including credit risk, liquidity risk, and market risk. The Company has established a risk management system to identify, measure, and manage these risks. The Company's financial instruments are primarily cash, accounts receivable, accounts payable, and other financial assets and liabilities. The Company's financial instruments are subject to various risks, including credit risk, liquidity risk, and market risk. The Company has established a risk management system to identify, measure, and manage these risks.

The Company's financial instruments are primarily cash, accounts receivable, accounts payable, and other financial assets and liabilities. The Company's financial instruments are subject to various risks, including credit risk, liquidity risk, and market risk. The Company has established a risk management system to identify, measure, and manage these risks.

1. The Company's financial instruments are primarily cash, accounts receivable, accounts payable, and other financial assets and liabilities. The Company's financial instruments are subject to various risks, including credit risk, liquidity risk, and market risk. The Company has established a risk management system to identify, measure, and manage these risks.

The Company's financial instruments are primarily cash, accounts receivable, accounts payable, and other financial assets and liabilities. The Company's financial instruments are subject to various risks, including credit risk, liquidity risk, and market risk. The Company has established a risk management system to identify, measure, and manage these risks.

The Company's financial instruments are primarily cash, accounts receivable, accounts payable, and other financial assets and liabilities. The Company's financial instruments are subject to various risks, including credit risk, liquidity risk, and market risk. The Company has established a risk management system to identify, measure, and manage these risks.

Notes to the Financial Statements

Ex 24 J 30, 2024

(A) (B)

II. $(C \rightarrow \bullet)$

(I) Various risks associated with financial instruments *(Continued)*

1. $C \rightarrow \neg (C \rightarrow \bullet)$

C

A

C

E

C

E

C

2-9

B

D

F

C

A

2. $\rightarrow$

Figure 1 is a schematic representation of the experimental design. It shows a sequence of events for three groups: C (Control), B (Bilateral), and A (Asymmetrical). The events are represented by various symbols and arrows indicating the flow of the experiment. Group C starts with a 12-second period, followed by a sequence of events including a 'C' label and a 'B' label. Group B starts with a 'C' label, followed by a 'B' label. Group A starts with a 'C' label, followed by a 'B' label. The events are represented by various symbols and arrows indicating the flow of the experiment.

Notes to the Financial Statements

En 30, 2024
(A B)

II. (C)

(I) Various risks associated with financial instruments (Continued)

2. (C)

C :
:

Closing balance							
	Instant	Within			Over	Total	
Items	repayment	1 year	1-2 years	2-5 years	5 years	undiscounted contract amount	Book value
A		112,544,938.03				112,544,938.03	112,544,938.03
		68,487,137.05				68,487,137.05	68,487,137.05
		111,000,000.00				111,000,000.00	111,000,000.00
		108,286,381.25				108,286,381.25	108,286,381.25
			287,545,000.00	314,094,120.00	166,585,549.65	768,224,669.65	768,224,669.65
			18,133,866.38	54,983,512.27	95,622,594.14	168,739,972.79	158,912,952.10
			25,945,947.15	45,352,431.95		71,298,379.10	64,227,913.88
		400,318,456.33	331,624,813.53	414,430,064.22	262,208,143.79	1,408,581,477.87	1,210,651,916.88

B						
I	I	1-2	2-5	5		B
	1,545,021.09				1,545,021.09	1,545,021.09
B	340,005,699.32	270,474,264.25	228,670,426.19	158,782,942.13	997,933,331.89	864,740,914.69
	28,643,888.99	44,408,365.80	71,261,748.80	69,158,488.54	213,472,492.13	191,883,421.75
	43,175,648.00	19,331,148.00	55,701,622.66		118,208,418.66	103,099,208.53
A	110,060,007.67				110,060,007.67	110,060,007.67
	150,270,575.15				150,270,575.15	150,270,575.15
	673,700,840.22	334,213,778.05	355,633,797.65	227,941,430.67	1,591,489,846.59	1,421,599,148.88

Notes to the Financial Statements

截至2024年6月30日

(A 资产负债表 (B 利润表 (C 现金流量表 (D 所有者权益变动表 (E 附注))

II. 关联方关系及其交易 (Continued)

(I) Various risks associated with financial instruments (Continued)

3. 信用风险
信用风险是指交易对手未能履行合同义务而导致公司产生财务损失的风险。信用风险主要产生于货币资金、应收账款、其他应收款、贷款及应收票据等。公司通过严格的信用评估和监控程序来管理信用风险。公司通常与信用评级较高的交易对手进行交易，并定期对交易对手的信用状况进行审查。此外，公司还通过分散交易对手来降低信用风险。

(1) 应收账款
应收账款是指公司已销售商品或提供服务但尚未收到款项的资产。公司通常根据客户的信用状况和交易历史来确定信用期限。公司定期对应收账款进行减值测试，并根据测试结果计提坏账准备。公司还通过加强催收工作来减少应收账款的余额。此外，公司还通过保理等方式来转移应收账款的信用风险。

截至2024年6月30日，公司应收账款余额为人民币1,234,567.89元，坏账准备余额为人民币123,456.78元。应收账款余额占流动资产总额的15.67%。

J 30, 2024, B9,911.08 (D 31, 2023: B4,019.00) B - 3%.

Notes to the Financial Statements

Ex 24 J 30, 2024

(A) (B)

II. $(C \rightarrow 1 \bullet)$

(I) Various risks associated with financial instruments *(Continued)*

3. $\begin{matrix} \uparrow & \uparrow \\ \text{---} & \text{---} \end{matrix} (C \text{ } \bullet)$

(3)

[illegible]

J 30, 2024,
C B2,170,524.92 (2023:
B2,269,330.55)
3%,
3%

III. D₁

[illegible]

1.                        

$$2\gamma \quad \text{---} \quad \gamma \quad \text{---} \quad \text{---} \quad \bullet \text{---} \gamma \quad \gamma \quad \bullet \quad \bullet \quad \gamma \quad \gamma \quad 1 \quad \text{---} \quad \text{---} \quad \gamma \text{---} \gamma \quad \gamma \quad \text{---} \quad \text{---}$$

$$\gamma \gamma : \gamma \text{---} \bullet \text{---} \gamma \quad \text{---} \quad \gamma \text{---} \bullet \text{---} \gamma$$
[illegible]

Notes to the Financial Statements

June 30, 2024
(A) (B)

III. D (C)

(I) Closing fair value of assets and liabilities measured at fair value

					Closing fair value			
					Measured at fair value at Level 1	Measured at fair value at Level 2	Measured at fair value at Level 3	Total
I. Continuous measurement of fair value								
F ₁							7,599,178.13	7,599,178.13
1. F ₁							7,599,178.13	7,599,178.13
(1)								
(2)							7,599,178.13	7,599,178.13
2. F ₁								
							64,751,652.55	64,751,652.55
1. F ₁							64,751,652.55	64,751,652.55
(1)								
(2)							64,751,652.55	64,751,652.55
Total assets with continuous measurement of fair value							72,350,830.68	72,350,830.68
F ₁							12,400,000.00	12,400,000.00
1. F ₁							12,400,000.00	12,400,000.00
(1)								
(2)								
(3)							12,400,000.00	12,400,000.00
2. F ₁								
Total liabilities with continuous measurement of fair value							12,400,000.00	12,400,000.00

Notes to the Financial Statements

截至 2024 年 6 月 30 日

(A 股上市财务报表)

III. 公允价值计量 (续)

- (II) 定性及定量估值技术和关键参数信息，适用于在持续和非持续公允价值计量中使用的第 3 级公允价值计量的项目

1. 对于在持续公允价值计量中使用的第 3 级公允价值计量的项目，公司采用估值技术确定其公允价值。估值技术是指使用可观察市场数据，通过估值模型确定资产或负债的公允价值。公司采用的估值技术包括：现金流量折现法、市场比较法等。公司采用的关键参数包括：折现率、可比公司的市盈率等。
2. 对于在非持续公允价值计量中使用的第 3 级公允价值计量的项目，公司采用估值技术确定其公允价值。估值技术是指使用可观察市场数据，通过估值模型确定资产或负债的公允价值。公司采用的估值技术包括：现金流量折现法、市场比较法等。公司采用的关键参数包括：折现率、可比公司的市盈率等。

Notes to the Financial Statements

English version
(A) (B)

I. General information of the parent company

(I) General information of the parent company

Wenzhou Kangning Hospital Co., Ltd. (Wenzhou Kangning Hospital Co., Ltd.)

(II) Information of the Company's subsidiaries

Wenzhou Kangning Hospital Co., Ltd. (Wenzhou Kangning Hospital Co., Ltd.)

(III) Information of the Company's joint ventures and associates

Wenzhou Kangning Hospital Co., Ltd. (Wenzhou Kangning Hospital Co., Ltd.)

Wenzhou Kangning Hospital Co., Ltd. (Wenzhou Kangning Hospital Co., Ltd.)

Name of joint venture or associate	Relationship with the Company
H A	A C
H H C	A C
H H C	A C
H H C	A C
C H H C	A C
F C	A C

Notes to the Financial Statements

Ex 24 J 30, 2024

(A)  (B) 

[illegible]

(IV) Information of other related parties

Name of other related parties	Other related parties' relationship with the Company
C 司 公 有 限 公 司	- 董事 司 公 有 限 公 司 董事 司 公 有 限 公 司
C 司 公 有 限 公 司	- 董事 司 公 有 限 公 司 董事 司 公 有 限 公 司
J 司 公 有 限 公 司	- 董事 司 公 有 限 公 司 董事 司 公 有 限 公 司
司 公 有 限 公 司 B 司 公 有 限 公 司 A 司 公 有 限 公 司	- 董事 司 公 有 限 公 司 董事 司 公 有 限 公 司
司 公 有 限 公 司 (寧 波 梅 山 保 稅 港 區 寬 展 投 資 管 理 合 夥 企 業 (有 限 合 夥))	- 董事 司 公 有 限 公 司 董事 司 公 有 限 公 司
司 公 有 限 公 司 E 司 公 有 限 公 司 H 司 公 有 限 公 司 C 司 公 有 限 公 司	- 董事 司 公 有 限 公 司 董事 司 公 有 限 公 司
H 司 公 有 限 公 司	- 董事 司 公 有 限 公 司 董事 司 公 有 限 公 司
司 公 有 限 公 司	- 董事 司 公 有 限 公 司 董事 司 公 有 限 公 司
司 公 有 限 公 司	- 董事 司 公 有 限 公 司 董事 司 公 有 限 公 司
司 公 有 限 公 司 H 司 公 有 限 公 司 G 司 公 有 限 公 司	- 董事 司 公 有 限 公 司 董事 司 公 有 限 公 司
(四 川 省 宏 濟 藥 業 有 限 責 任 公 司)	- 董事 司 公 有 限 公 司 董事 司 公 有 限 公 司
C 司 公 有 限 公 司	- 董事 司 公 有 限 公 司 董事 司 公 有 限 公 司
司 公 有 限 公 司 H 司 公 有 限 公 司 C 司 公 有 限 公 司	- 董事 司 公 有 限 公 司 董事 司 公 有 限 公 司
司 公 有 限 公 司 E 司 公 有 限 公 司 C 司 公 有 限 公 司 C 司 公 有 限 公 司	- 董事 司 公 有 限 公 司 董事 司 公 有 限 公 司
司 公 有 限 公 司 H 司 公 有 限 公 司 C 司 公 有 限 公 司	- 董事 司 公 有 限 公 司 董事 司 公 有 限 公 司
H 司 公 有 限 公 司 H 司 公 有 限 公 司 C 司 公 有 限 公 司	- 董事 司 公 有 限 公 司 董事 司 公 有 限 公 司
A 司 公 有 限 公 司	- 董事 司 公 有 限 公 司 董事 司 公 有 限 公 司
司 公 有 限 公 司 H 司 公 有 限 公 司 C 司 公 有 限 公 司	- 董事 司 公 有 限 公 司 董事 司 公 有 限 公 司

Notes to the Financial Statements

English version is authoritative. In case of discrepancy, the Chinese version shall prevail.
(A) (B)

(C)

(V) Information on related party transactions

1. (C)

Related party	Amount for the period	
F. A. C. .	46,490.62	
C. .	17,960.18	

Related party	Amount for the period	
H. C.	1,485,148.52	1,485,148.50
H. H. C. .	84,905.66	

Notes to the Financial Statements

For the period ending June 30, 2024
(All amounts are in RMB million unless otherwise specified)

1. Information on related party transactions (Continued)

(V) Information on related party transactions (Continued)

2. Guarantees provided by the Company:

Name of guaranteed party	Guaranteed amount	Commencement date	Expiry date	Whether the guarantee has been fulfilled
Hangzhou Kangning Hospital Co., Ltd.	14,660,000.00	2019/9/10	2029/8/20	
Hangzhou Kangning Hospital Co., Ltd.	10,280,000.00	2020/1/1	2029/8/20	
Hangzhou Kangning Hospital Co., Ltd.	3,320,000.00	2020/12/22	2029/8/20	
Hangzhou Kangning Hospital Co., Ltd.	2,200,000.00	2020/9/27	2029/8/20	
Hangzhou Kangning Hospital Co., Ltd.	2,200,000.00	2020/9/27	2029/8/20	
Hangzhou Kangning Hospital Co., Ltd.	3,050,000.00	2021/3/1	2029/8/20	
Hangzhou Kangning Hospital Co., Ltd.	3,050,000.00	2021/3/1	2029/8/20	
Hangzhou Kangning Hospital Co., Ltd.	45,000,000.00	2023/7/3	2037/12/31	
Hangzhou Kangning Hospital Co., Ltd.	15,000,000.00	2023/7/31	2037/12/31	
Hangzhou Kangning Hospital Co., Ltd.	10,116,550.00	2023/10/25	2037/12/31	
Hangzhou Kangning Hospital Co., Ltd.	5,007,200.00	2023/11/24	2037/12/31	
Hangzhou Kangning Hospital Co., Ltd.	5,000,000.00	2020/3/25	2024/12/20	
Hangzhou Kangning Hospital Co., Ltd.	17,500,000.00	2020/5/22	2024/12/20	
Hangzhou Kangning Hospital Co., Ltd.	60,000,000.00	2023/10/9	2031/10/9	
Hangzhou Kangning Hospital Co., Ltd.	2,000,000.00	2023/3/31	2024/3/29	
Hangzhou Kangning Hospital Co., Ltd.	26,000,000.00	2023/4/3	2032/3/2	

Notes to the Financial Statements

Enacted on June 30, 2024
(Approved by the Board of Directors)

1. Information on related party transactions (Continued)

(V) Information on related party transactions (Continued)

2. Guarantees provided (Continued)

Cash

Name of guarantor	Guaranteed amount	Commencement date	Expiry date	Whether the guarantee has been fulfilled
Wenzhou Kangning Hospital Co., Ltd.	200,000,000.00		2026/12/24	
Wenzhou Kangning Hospital Co., Ltd.	200,000,000.00		2026/12/24	
Cash	200,000,000.00		2026/12/24	
Cash	66,474,000.00		2026/12/10	
Wenzhou Kangning Hospital Co., Ltd.	200,000,000.00		2026/12/24	
G	24,000,000.00	2020/6/30	2027/6/30	
G	79,642,127.25	2021/11/29	2028/11/29	
G				
	180,950,000.00	2020/10/26	2026/10/25	
G	70,000,000.00	2023/11/8	2026/11/15	
G	135,000,000.00	2023/12/14	2024/12/14	
G	14,660,000.00	2019/9/10	2029/8/20	
G	10,280,000.00	2020/1/1	2029/8/20	
G	3,320,000.00	2020/12/22	2029/8/20	
G	2,200,000.00	2020/9/27	2029/8/20	
G	2,200,000.00	2020/9/27	2029/8/20	
G	3,050,000.00	2021/3/1	2029/8/20	
G	3,050,000.00	2021/3/1	2029/8/20	
G	45,000,000.00	2023/7/3	2037/12/31	
G	15,000,000.00	2023/7/31	2037/12/31	
G	10,116,550.00	2023/10/25	2037/12/31	
G	5,007,200.00	2023/11/24	2037/12/31	
G	5,000,000.00	2020/3/25	2024/12/20	
G	17,500,000.00	2020/5/22	2024/12/20	
G				
Cash				
Wenzhou Kangning Hospital Co., Ltd.	60,000,000.00	2023/10/9	2031/10/9	

Notes to the Financial Statements

For the period ending June 30, 2024
(All amounts are in RMB unless otherwise specified)

1. Information on related party transactions (Continued)

(V) Information on related party transactions (Continued)

3. Placements from banks and other financial institutions

Related parties	Placement amount	Commencement date	Expiry date	Description
Placements from banks and other financial institutions				
Bank of China	900,000.00	2023/1/14	2024/1/14	Short-term loan
China Construction Bank	4,800,000.00	2023/6/7	2024/6/7	Short-term loan
Industrial Bank	1,095,000.00	2023/9/29		Short-term loan
Bank of Communications	2,508,250.00	2022/6/13		Short-term loan
Bank of Shanghai	2,000,000.00	2022/6/15	2023/6/14	Short-term loan
Placements with banks and other financial institutions				
Bank of China	13,500,000.00	2023/1/10	2026/1/9	Long-term loan
Bank of Communications	33,273,577.42	2020/11/19	2023/5/18	Long-term loan
Bank of Shanghai	10,204,311.69	2015/6/1		Long-term loan
Bank of China	3,490,447.08	2015/9/1		Long-term loan

4. Placements with banks and other financial institutions

Item	Amount for the current period	Amount for the previous period
Placements from banks and other financial institutions	3,600,689.93	3,215,037.52
Placements with banks and other financial institutions	436,155.63	

Notes to the Financial Statements

English version is authoritative in case of discrepancy with the Chinese version.
(A) (B)

(C) (B)

(VI) Receivables from and payables to related parties and other unsettled items

1.

Items	Related parties	Balance as at the end of the period		B	
		Book balance	Provision for bad debts		
A	H				
	H C			65,000.00	3,250.00
	H A				
	C	1,522.85	15.23	1,522.85	15.23
	H	635,000.00	6,350.00	635,000.00	6,350.00
	H C	23,066,977.13	23,066,977.13	34,005,471.02	1,700,273.55
	C H	13,903,890.41	695,194.52	14,290,027.40	714,501.37
	C H	10,204,311.69	10,204,311.69	10,204,311.69	10,204,311.69
	C C	3,490,447.08	3,490,447.08	3,490,447.08	3,490,447.08
	C	16,836.66	841.83	16,836.66	841.83
	C G	100,000.00	1,000.00	100,000.00	1,000.00
	C	80,004.00	800.04	80,004.00	800.04
	C	75,187.50	3,759.38	105,187.50	5,259.38
	J D	431,587.50	21,579.38	479,707.50	23,985.38

Notes to the Financial Statements

December 31, 2024
(Amount in thousands of RMB)

(Continued)

(VI) Receivables from and payables to related parties and other unsettled items (Continued)

2.

		Book balance as at the end of the period	
Items	Related parties		
A	H	78,950.00	167,677.40
		3,833,341.95	3,702,846.16
		994,803.26	962,492.04
		3,677,029.66	3,599,626.28
		1,095,000.00	1,095,000.00
		4,839,241.37	2,021,750.00
			6,347,133.33
			16,997,627.91
		2,508,250.00	3,108,250.00
		92,081.16	94,276.16
		2,333,369.95	2,261,567.19
		291,842.74	291,842.74
		93,142.79	93,142.79
		19,983.98	19,983.98

Notes to the Financial Statements

For the period ending June 30, 2024
(Amount in thousands of RMB)

1. (C)

(VII) Five Individuals with Highest Remunerations

For the period ending June 30, 2024, the five individuals with the highest remuneration (June 30, 2023: 0), were as follows:

Items	Amount for the current period	Amount for the corresponding period of the previous year
Salary	1,174,589.67	2,096,606.59
Performance bonus	17,942.58	
	1,192,532.25	2,096,606.59

Remuneration band	Number of individuals for the current period	Number of individuals for the corresponding period of the previous year
500,000-1,000,000.00	3	4
Over 1,000,000.00	0	1
	3	5

Notes to the Financial Statements

Ex 24 J 30, 2024

(A)  (B) 

(I) Summary of share-based payment

1. $E \cap I \cap J \cap K$

[illegible]

C

48 (J 30, 2023: 100-101; J 30, 2024: 100-101). (J 30, 2023: 100-101; J 30, 2024: 100-101).

[illegible]

Notes to the Financial Statements

截至2024年6月30日

(A 和 B 列示的金额单位为人民币元)

续上表 (C 列示)

(I) Summary of share-based payment (Continued)

2. H 列示的金额 (C 列示)

截至2024年6月30日

截至2024年6月30日

C 列示的金额

48

(II) Equity-settled share-based payment

截至2024年6月30日

B 列示的金额 B10.87 B10.47

截至2024年6月30日

截至2024年6月30日

截至2024年6月30日

A 列示的金额

A 截至2024年6月30日 B45,625,047.88.

截至2024年6月30日 B767,673.68.

Notes to the Financial Statements

Wen Zhou Kang Ning Hospital Co., Ltd.
(A joint stock company limited by shares)

I. Significant commitments

(I) Significant commitments

1. Significant commitments

The company has no significant commitments as of June 30, 2024.

	June 30, 2024	December 31, 2023
Significant commitments	55,890,951.92	122,040,000.00
	55,890,951.92	122,040,000.00

2. Significant commitments

As of June 30, 2024, the company has no significant commitments.

(II) Contingencies

The company has no contingencies as of June 30, 2024.

II. Profit distribution

(I) Profit distribution

The company has no profit distribution as of June 30, 2024.

The company has no profit distribution as of June 30, 2024.

Notes to the Financial Statements

Feb 28, 2024

(A) $\rightarrow$ (B)

III. C

$\frac{1}{2} \pi$ $\frac{1}{2} \pi$ C $\frac{1}{2} \pi$ $\frac{1}{2} \pi$ $\frac{1}{2} \pi$ $\frac{1}{2} \pi$

[illegible]

C

A

	Balance as at the end of the period	B 52.79%
D 2 / 2020	52.58%	53.79%

1.

(I) Segment Information

Notes to the Financial Statements

End of June 30, 2024
(Amount in thousands of RMB)

(I) Accounts receivable

1. Aging method

	Balance as at the end of the period	B End of period
Aging		
1 year or less	51,071,471.71	48,552,078.47
1-2 years	11,406,851.48	257,315.13
2-3 years	257,315.13	709,878.26
3 years or more	4,616,400.13	3,906,521.87
Provision for doubtful accounts	67,352,038.45	53,425,793.73
Net accounts receivable	11,362,291.77	5,359,236.04
	55,989,746.68	48,066,557.69

Notes to the Financial Statements

English version is authoritative in case of discrepancy with the Chinese version.
(A) (B)

(I) Accounts receivable (Continued)

Category	Balance as at the end of the period				B			
	Book balance		Provision for bad debts		B		B	
	Amount	Proportion (%)	Amount	Proportion of provision (%)	Carrying amount	A	A	C
1. Accounts receivable	4,873,715.26	7.24	4,873,715.26	100.00	4,873,715.26	4,873,715.26	4,873,715.26	
2. Accounts receivable	4,873,715.26	7.24	4,873,715.26	100.00	4,873,715.26	4,873,715.26	4,873,715.26	
3. Accounts receivable	57,018,962.00	92.76	6,488,576.51	11.38	50,530,385.49	48,552,078.47	485,520.78	48,066,557.69
4. Accounts receivable	5,459,361.19	8.11			5,459,361.19			
5. Accounts receivable	57,018,962.00	84.66	6,488,576.51	11.38	50,530,385.49	48,552,078.47	485,520.78	48,066,557.69
	67,352,038.45	100.00	11,362,291.77		55,989,746.68	53,425,793.73	5,359,236.04	48,066,557.69

1. Accounts receivable

Items	Balance as at the end of the period				B	
	Book balance	Provision for bad debts	Proportion of provision (%)	Reason for the provision	B	
	4,873,715.26	4,873,715.26	100.00	Not expect to be recoverable	4,873,715.26	4,873,715.26
	4,873,715.26	4,873,715.26			4,873,715.26	4,873,715.26

Notes to the Financial Statements

English version is authoritative in case of discrepancy with the Chinese version.
(A) (B)

(C)

(I) Accounts receivable (Continued)

2. A (C)

Items	Balance as at the end of the period		
	Accounts receivable	Provision for bad debt	Proportion of provision (%)
	57,018,962.00	6,488,576.51	11.38
	57,018,962.00	6,488,576.51	

3.

Category	B	Changes in the current period			Balance as at the end of the period
		Provided for	Recovered or reversed	Written-back or written-off	
	4,873,715.26				4,873,715.26
	485,520.78	6,003,055.73			6,488,576.51
	5,359,236.04	6,003,055.73			11,362,291.77

Notes to the Financial Statements

December 31, 2024
(All amounts in RMB)

(II) Other receivables

Items	Balance as at the end of the period	B RMB
Prepaid expenses	787,500.00	
Due from related parties	14,400,000.00	14,400,000.00
Other receivables	607,735,083.60	586,048,325.58
	622,922,583.60	600,448,325.58

1. Prepaid expenses

Prepaid expenses are incurred by the Company for the purchase of goods and services.

Items	Balance as at the end of the period	B RMB
Prepaid medical services	787,500.00	
	787,500.00	

2. Due from related parties

Item (or investee)	Balance as at the end of the period	B RMB
C H C . .	4,400,000.00	4,400,000.00
H C . .	10,000,000.00	10,000,000.00
	14,400,000.00	14,400,000.00

Notes to the Financial Statements

English version is authoritative in case of discrepancy with the Chinese version.
(A) (B)

(II) Other receivables (Continued)

3. (1) Aging

Aging	Balance as at the end of the period	B
1	571,062,190.36	552,853,728.97
1 2	5,089,808.65	34,594,797.65
2 3	33,287,580.41	496,167.22
3	1,158,794.57	908,479.96
	610,598,373.99	588,853,173.80
	2,863,290.39	2,804,848.22
	607,735,083.60	586,048,325.58

(2) Detailed breakdown of other receivables

Category	Balance as at the end of the period				B				
	Book balance		Provision for bad debts		B		B		B
	Amount	Proportion (%)	Amount	Proportion of provision (%)	Book value	A	(%)	A	
1	610,598,373.99	100.00	2,863,290.39	0.47	607,735,083.60	588,853,173.80	100.00	2,804,848.22	0.48
2	80,464,046.88	13.18	2,863,290.39	3.56	77,600,756.49	75,462,768.59	12.82	2,804,848.22	3.72
3	530,134,327.11	86.82			530,134,327.11	513,390,405.21			513,390,405.21
	610,598,373.99	100.00	2,863,290.39	/	607,735,083.60	588,853,173.80	100.00	2,804,848.22	/

Notes to the Financial Statements

For the period ending June 30, 2024
(Amount in thousands of RMB)

(Continued)

(II) Other receivables (Continued)

3. Other receivables (Continued)

(2) Details of other receivables as at the end of the period (Continued)

As at June 30, 2024, the Company's other receivables consist of the following:

Name	Balance as at the end of the period		
	Other receivables	Provision for bad debts	Proportion of provision (%)
A	80,464,046.88	2,863,290.39	3.56
A	530,134,327.11		
	610,598,373.99	2,863,290.39	

Ex 24 J 30, 2024

(A)  (B) 

$$(C_0 \otimes C_1) \otimes C_2 = C_0 \otimes (C_1 \otimes C_2)$$

(II) Other receivables (Continued)

3. ~~user~~ γ (C γ •)

(3) D 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 10

	Stage I	Stage II	Stage III	
		Lifetime ECL (not credit impaired)	Lifetime ECL (credit impaired)	
Provision for bad debts	12-month ECL			Total
B				
	2,804,848.22			2,804,848.22
B				
	58,442.17			58,442.17
B	2,863,290.39			2,863,290.39

(A) (B)

(II) Other receivables (Continued)

(3) $D \cap \dots \cap D \cap \dots \cap (C \cap \dots)$

	Stage I	Stage II	Stage III	
		Lifetime ECL (not credit impaired)	Lifetime ECL (credit impaired)	Total
B	12-month ECL			
B	588,853,173.80			588,853,173.80
B				
A	21,745,200.19			21,745,200.19
D				
B	610,598,373.99			610,598,373.99

Notes to the Financial Statements

English version is authoritative. In case of discrepancy, the Chinese version shall prevail.
(A) (B)

(II) Other receivables (Continued)

3. (C)

(4)

Category	B	Changes in the current period				Balance as at the end of the period
		Provided for	Recovered or reversed	Written-back or written-off	Other changes	
	2,804,848.22	58,442.17				2,863,290.39
	2,804,848.22	58,442.17				2,863,290.39

(5)

Nature of receivables	Book balance as at the end of the period	B
A	530,134,327.11	513,390,405.21
I	25,957,550.96	20,480,175.04
D	5,716,830.00	5,920,030.00
	181,832.86	767,065.13
A	48,607,833.06	48,295,498.42
	610,598,373.99	588,853,173.80

Notes to the Financial Statements

English version is authoritative. In case of discrepancy, the Chinese version shall prevail.
(A) (B)

(III) Long-term equity investments

Items	Balance as at the end of the period		B	
	Book balance	Provision for impairment Book value	B	B
Investment in subsidiaries	698,830,684.03	698,830,684.03	691,561,513.66	691,561,513.66
Investment in associates	94,549,945.13	94,549,945.13	94,421,925.51	94,421,925.51
Total	793,380,629.16	793,380,629.16	785,983,439.17	785,983,439.17

Notes to the Financial Statements

Unit: RMB Yuan
(A) (B)

1. Long-term equity investments (Continued)	Increase/decrease in the current period					Balance as at the end of the period	Balance of the impairment provision as at the end of the period
	Investees	B	Increase in investment	Decrease in investment	Provision for impairment for the current period		
1. /	Investees	B	Increase in investment	Decrease in investment	Provision for impairment for the current period	Balance as at the end of the period	Balance of the impairment provision as at the end of the period
	1. /	15,500,000.00				15,500,000.00	
	2. /	500,000.00				500,000.00	
	3. /	204,666,253.87				204,709,938.51	
	4. /	52,697,737.50				52,697,737.50	
	5. /	2,133,258.38				2,133,258.38	
	6. /	27,687,093.11				27,687,093.11	
	7. /	32,856,644.25				32,856,644.25	
	8. /	4,799,071.39				4,803,343.43	
	9. /	53,500,000.00				53,515,660.04	
2. /	Investees	B	Increase in investment	Decrease in investment	Provision for impairment for the current period	Balance as at the end of the period	Balance of the impairment provision as at the end of the period
	1. /	40,800,000.00	7,200,000.00			48,000,000.00	
	2. /	10,000,000.00				10,000,000.00	
	3. /	154,744,700.00				154,750,253.65	
	4. /	29,051,800.00				29,051,800.00	
	5. /	40,954,955.16				40,954,955.16	
	6. /	14,510,000.00				14,510,000.00	
	7. /	500,000.00				500,000.00	
	8. /	6,660,000.00				6,660,000.00	
	9. /	691,561,513.66	7,200,000.00			698,830,684.03	

Notes to the Financial Statements

Feb 28, 2024

(A) (B)

Long-term equity investments (Continued)									
		Increase/decrease in the current period							
		B						Balance of the impairment provision as at the end of the period	
Investees		Investment profit/loss recognized under equity method	Other comprehensive income adjustment	Cash dividends or profits declared and paid	Other equity changes	Impairment provision	Others		
A									
H	A								
	C	16,018,884.98		687,659.39				16,706,544.37	
H	C	56,841,432.86		-166,415.53				56,675,017.33	
	H								
	C	21,561,607.67		-393,224.24				21,168,383.43	
		94,421,925.51		128,019.62				94,549,945.13	

Notes to the Financial Statements

English version is authoritative. In case of discrepancy, the Chinese version shall prevail.
(A) (B)

(IV) Revenue and cost of sales

1.

Items	Amount for the current period		A	
	Revenue	Cost		C
1	185,247,902.83	130,785,130.41	174,575,542.75	130,786,397.79
2	7,845,218.13		1,629,256.25	
	193,093,120.96	130,785,130.41	176,204,799.00	130,786,397.79

B

Items	Amount for the current period	A
1	185,247,902.83	174,575,542.75
2	185,247,902.83	174,575,542.75
3	7,845,218.13	1,629,256.25
4	6,472,852.67	
5	209,955.19	512,200.28
6	1,162,410.27	1,117,055.97
	193,093,120.96	176,204,799.00

2. D

Item	Time to fulfill performance obligations	Major payment terms	Nature of the goods that the Company promises to transfer	Do we take the major responsibility	Expected amounts that the Company has undertaken to return to customers	Types of quality assurance provided by the Company and associated obligations
1	A		D ₁			
2	B ₁					

Notes to the Financial Statements

For the period from January 1 to June 30, 2024
(Amount in thousands of RMB)

(Continued)

(V) Investment income

Items	Amount for the current period	Amount at the beginning of the period
Dividend income from equity investments	14,061,318.98	
Dividend income from debt investments	128,019.62	816,165.55
Interest income from debt investments		-1,591,713.27
	14,189,338.60	-775,547.72

Definitions

A ● 1 C	11	● 1	1 B ●
B 11 11 H 1	B 11 11 H 1 C ., ●. (北京怡寧醫院有限公司), / C 1 11 ● 11 11 A 17, 2015, C 1 11 11 - ● 11 11		
B ● D 11 11 B ●	11 ● 11 11 C 1 1		
C 11 11 H 1	C 11 11 H 1 C ., ●. (蒼南康寧醫院有限公司), / C 1 11 ● 11 11 J 15, 2012, C 1 11 11 ● 11 11		
C 11 11 11 11 C 11	C 11 11 11 11 C 11 C ., ●. (蒼南怡寧護理中心有限公司), 11 ● 11 / C 1 11 ● 11 11 11 9, 2021, C 1 11 11 11 11 11 ● 11 11		
C 11 11	C 11 11 11 / 11 11 C 1		
C ● 11 11 H 1	C ● J 11 11 11 / 11 11 H 1 C ., ●. (成都怡寧醫院有限公司), 11 11 H 1 C ., ●. (成都怡寧醫院有限公司), / C 1 11 ● 11 11 J 29, 2010, C 1 11 11 11 - 11 11		
C 11 11 11 11 H 1	11 11 11 H 1 C ., ●. 11 11 11 11 11 11 11 11 B ● H 1 E / C, H 11 11 11 11 11 11 (C ● : 2120)		
CG C ●	C 11 G 11 C ● 11 11 A ● 1 C1 H 11 11		
C 11 11 / 11 H 1	C 11 11 / 11 11 H 1 C ., ●. (長春康林心理醫院有限公司), / C 1 11 ● 11 11 F 11 16, 2016, C 1 11 11 11 - 11 11		
C 11 11 H 1	C 11 11 11 H 1 H 1 C ., ●. (淳安康寧黃鋒醫院有限公司), / C 1 11 ● 11 11 A 11 16, 2020, C 1 11 11 11 - 11 11		
D 11 11 ()	11 11 () C 1 1		



Definitions

D 股 ()	本公司 () 的 股 份 中 的 C 股 份 , 其 股 份 面 值 為 B1.00 元 , 其 股 份 的 名 稱 為 B 股 份 , 其 股 份 的 名 稱 為 B 股 份
D 股 的 持 有 人	D 股 的 持 有 人 為 洞 口 樂 寧 醫 院 有 限 公 司 (洞 口 樂 寧 醫 院 有 限 公 司), 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份
EG	本公司 的 股 份 中 的 C 股 份 , 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份
G 股 的 持 有 人	G 股 的 持 有 人 為 溫 州 怡 寧 老 年 醫 院 有 限 公 司 (溫 州 怡 寧 老 年 醫 院 有 限 公 司), 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份
G 股 的 持 有 人	C 股 份 的 持 有 人 為 冠 縣 怡 寧 醫 院 有 限 公 司 (冠 縣 怡 寧 醫 院 有 限 公 司), 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份
G 股 的 持 有 人	G 股 的 持 有 人 為 冠 縣 怡 寧 醫 院 有 限 公 司 (冠 縣 怡 寧 醫 院 有 限 公 司), 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份
H 股 ()	本公司 的 股 份 中 的 C 股 份 () 的 股 份 面 值 為 B1.00 元 , 其 股 份 的 名 稱 為 B 股 份 , 其 股 份 的 名 稱 為 B 股 份
H 股 的 持 有 人	H 股 的 持 有 人 為 荷 澤 怡 寧 精 神 病 醫 院 有 限 公 司 (荷 澤 怡 寧 精 神 病 醫 院 有 限 公 司), 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份
H D 股 的 持 有 人	H 股 的 持 有 人 為 荷 澤 怡 寧 精 神 病 醫 院 有 限 公 司 (荷 澤 怡 寧 精 神 病 醫 院 有 限 公 司), 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份
H 股 的 持 有 人	H 股 的 持 有 人 為 荷 澤 怡 寧 精 神 病 醫 院 有 限 公 司 (荷 澤 怡 寧 精 神 病 醫 院 有 限 公 司), 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份
H 股 的 持 有 人	G 股 的 持 有 人 為 溫 州 怡 寧 老 年 醫 院 有 限 公 司 (溫 州 怡 寧 老 年 醫 院 有 限 公 司), 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份
H 股 的 持 有 人	H 股 的 持 有 人 為 荷 澤 怡 寧 精 神 病 醫 院 有 限 公 司 (荷 澤 怡 寧 精 神 病 醫 院 有 限 公 司), 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份 , 其 股 份 的 名 稱 為 C 股 份

Definitions

H	H	H	H	C., . (淮南康寧醫院有限公司), C 22, 2017, C
I	()	D	E	I
J	H	J	H	C., . (縉雲舒寧醫院有限公司), C 15, 2019, C
	H		H	C., . (龍泉康寧醫院有限公司), C 6, 2023, C
	H		H	C., . (婁底市康樂康寧醫院有限責任公司), C 28, 2017, C
	H		H	C., . (溫州鹿城怡寧醫院有限公司), C 2, 2020, C
	H		H	C., . (臨海慈寧醫院有限公司), C 11, 2020, C
	H		H	C., . (南京怡寧醫院有限公司), C 22, 2018, C
				C

Definitions

C

A C3 H

D I

 C

[illegible]

平陽長庚怡寧醫院有限公司, 14, 2021,

平陽康寧醫院有限公司), 2, 2015,

1. 2018年1月1日至2018年12月31日止，本公司及子公司（浦江怡寧黃鋒醫院有限公司），

1. C₁ C₂ H₁ H₂ C₃ C₄ C₅ C₆ C₇ C₈ C₉ C₁₀ C₁₁ C₁₂ C₁₃ C₁₄ C₁₅ C₁₆ C₁₇ C₁₈ C₁₉ C₂₀ C₂₁ C₂₂ C₂₃ C₂₄ C₂₅ C₂₆ C₂₇ C₂₈ C₂₉ C₃₀ C₃₁ C₃₂ C₃₃ C₃₄ C₃₅ C₃₆ C₃₇ C₃₈ C₃₉ C₄₀ C₄₁ C₄₂ C₄₃ C₄₄ C₄₅ C₄₆ C₄₇ C₄₈ C₄₉ C₅₀ C₅₁ C₅₂ C₅₃ C₅₄ C₅₅ C₅₆ C₅₇ C₅₈ C₅₉ C₆₀ C₆₁ C₆₂ C₆₃ C₆₄ C₆₅ C₆₆ C₆₇ C₆₈ C₆₉ C₇₀ C₇₁ C₇₂ C₇₃ C₇₄ C₇₅ C₇₆ C₇₇ C₇₈ C₇₉ C₈₀ C₈₁ C₈₂ C₈₃ C₈₄ C₈₅ C₈₆ C₈₇ C₈₈ C₈₉ C₉₀ C₉₁ C₉₂ C₉₃ C₉₄ C₉₅ C₉₆ C₉₇ C₉₈ C₉₉ C₁₀₀ C₁₀₁ C₁₀₂ C₁₀₃ C₁₀₄ C₁₀₅ C₁₀₆ C₁₀₇ C₁₀₈ C₁₀₉ C₁₁₀ C₁₁₁ C₁₁₂ C₁₁₃ C₁₁₄ C₁₁₅ C₁₁₆ C₁₁₇ C₁₁₈ C₁₁₉ C₁₂₀ C₁₂₁ C₁₂₂ C₁₂₃ C₁₂₄ C₁₂₅ C₁₂₆ C₁₂₇ C₁₂₈ C₁₂₉ C₁₃₀ C₁₃₁ C₁₃₂ C₁₃₃ C₁₃₄ C₁₃₅ C₁₃₆ C₁₃₇ C₁₃₈ C₁₃₉ C₁₄₀ C₁₄₁ C₁₄₂ C₁₄₃ C₁₄₄ C₁₄₅ C₁₄₆ C₁₄₇ C₁₄₈ C₁₄₉ C₁₅₀ C₁₅₁ C₁₅₂ C₁₅₃ C₁₅₄ C₁₅₅ C₁₅₆ C₁₅₇ C₁₅₈ C₁₅₉ C₁₆₀ C₁₆₁ C₁₆₂ C₁₆₃ C₁₆₄ C₁₆₅ C₁₆₆ C₁₆₇ C₁₆₈ C₁₆₉ C₁₇₀ C₁₇₁ C₁₇₂ C₁₇₃ C₁₇₄ C₁₇₅ C₁₇₆ C₁₇₇ C₁₇₈ C₁₇₉ C₁₈₀ C₁₈₁ C₁₈₂ C₁₈₃ C₁₈₄ C₁₈₅ C₁₈₆ C₁₈₇ C₁₈₈ C₁₈₉ C₁₉₀ C₁₉₁ C₁₉₂ C₁₉₃ C₁₉₄ C₁₉₅ C₁₉₆ C₁₉₇ C₁₉₈ C₁₉₉ C₂₀₀ C₂₀₁ C₂₀₂ C₂₀₃ C₂₀₄ C₂₀₅ C₂₀₆ C₂₀₇ C₂₀₈ C₂₀₉ C₂₁₀ C₂₁₁ C₂₁₂ C₂₁₃ C₂₁₄ C₂₁₅ C₂₁₆ C₂₁₇ C₂₁₈ C₂₁₉ C₂₂₀ C₂₂₁ C₂₂₂ C₂₂₃ C₂₂₄ C₂₂₅ C₂₂₆ C₂₂₇ C₂₂₈ C₂₂₉ C₂₃₀ C₂₃₁ C₂₃₂ C₂₃₃ C₂₃₄ C₂₃₅ C₂₃₆ C₂₃₇ C₂₃₈ C₂₃₉ C₂₄₀ C₂₄₁ C₂₄₂ C₂₄₃ C₂₄₄ C₂₄₅ C₂₄₆ C₂₄₇ C₂₄₈ C₂₄₉ C₂₅₀ C₂₅₁ C₂₅₂ C₂₅₃ C₂₅₄ C₂₅₅ C₂₅₆ C₂₅₇ C₂₅₈ C₂₅₉ C₂₆₀ C₂₆₁ C₂₆₂ C₂₆₃ C₂₆₄ C₂₆₅ C₂₆₆ C₂₆₇ C₂₆₈ C₂₆₉ C₂₇₀ C₂₇₁ C₂₇₂ C₂₇₃ C₂₇₄ C₂₇₅ C₂₇₆ C₂₇₇ C₂₇₈ C₂₇₉ C₂₈₀ C₂₈₁ C₂₈₂ C₂₈₃ C₂₈₄ C₂₈₅ C₂₈₆ C₂₈₇ C₂₈₈ C₂₈₉ C₂₉₀ C₂₉₁ C₂₉₂ C₂₉₃ C₂₉₄ C₂₉₅ C₂₉₆ C₂₉₇ C₂₉₈ C₂₉₉ C₃₀₀ C₃₀₁ C₃₀₂ C₃₀₃ C₃₀₄ C₃₀₅ C₃₀₆ C₃₀₇ C₃₀₈ C₃₀₉ C₃₁₀ C₃₁₁ C₃₁₂ C₃₁₃ C₃₁₄ C₃₁₅ C₃₁₆ C₃₁₇ C₃₁₈ C₃₁₉ C₃₂₀ C₃₂₁ C₃₂₂ C₃₂₃ C₃₂₄ C₃₂₅ C₃₂₆ C₃₂₇ C₃₂₈ C₃₂₉ C₃₃₀ C₃₃₁ C₃₃₂ C₃₃₃ C₃₃₄ C₃₃₅ C₃₃₆ C₃₃₇ C₃₃₈ C₃₃₉ C₃₄₀ C₃₄₁ C₃₄₂ C₃₄₃ C₃₄₄ C₃₄₅ C₃₄₆ C₃₄₇ C₃₄₈ C₃₄₉ C₃₅₀ C₃₅₁ C₃₅₂ C₃₅₃ C₃₅₄ C₃₅₅ C₃₅₆ C₃₅₇ C₃₅₈ C₃₅₉ C₃₆₀ C₃₆₁ C₃₆₂ C₃₆₃ C₃₆₄ C₃₆₅ C₃₆₆ C₃₆₇ C₃₆₈ C₃₆₉ C₃₇₀ C₃₇₁ C₃₇₂ C₃₇₃ C₃₇₄ C₃₇₅ C₃₇₆ C₃₇₇ C₃₇₈ C₃₇₉ C₃₈₀ C₃₈₁ C₃₈₂ C₃₈₃ C₃₈₄ C₃₈₅ C₃₈₆ C₃₈₇ C₃₈₈ C₃₈₉ C₃₉₀ C₃₉₁ C₃₉₂ C₃₉₃ C₃₉₄ C₃₉₅ C₃₉₆ C₃₉₇ C₃₉₈ C₃₉₉ C₄₀₀ C₄₀₁ C₄₀₂ C₄₀₃ C₄₀₄ C₄₀₅ C₄₀₆ C₄₀₇ C₄₀₈ C₄₀₉ C₄₁₀ C₄₁₁ C₄₁₂ C₄₁₃ C₄₁₄ C₄₁₅ C₄₁₆ C₄₁₇ C₄₁₈ C

Figure 1: Comparison of the proposed method with existing methods. The figure shows the performance of the proposed method (B1.50) compared to existing methods (D1, D2, D3, D4, D5, D6, D7, D8, D9, D10, D11, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21, D22, D23, D24, D25, D26, D27, D28, D29, D30, D31, D32, D33, D34, D35, D36, D37, D38, D39, D40, D41, D42, D43, D44, D45, D46, D47, D48, D49, D50, D51, D52, D53, D54, D55, D56, D57, D58, D59, D60, D61, D62, D63, D64, D65, D66, D67, D68, D69, D70, D71, D72, D73, D74, D75, D76, D77, D78, D79, D80, D81, D82, D83, D84, D85, D86, D87, D88, D89, D90, D91, D92, D93, D94, D95, D96, D97, D98, D99, D100) across different metrics (e.g., accuracy, precision, recall, F1 score, etc.). The proposed method (B1.50) is shown to outperform existing methods in most metrics.

青田康寧醫院有限公司, A 頁 1, 2011,

1. 衢州市怡寧醫院有限公司, 2015, 10月21日

30, 2024

Definitions

除非另有说明，本报告中所有金额均以人民币元为单位，并保留两位小数。
B
C
F
(C 571 H),
B1.00 ,
D H
H (深圳怡寧醫院, (深圳市怡寧醫院有限公司)),
22, 2014, C
12 B

Definitions

本公司之附屬公司，即溫州怡寧心理互聯網醫院有限公司（怡寧心理互聯網醫院（溫州）有限公司），於2020年10月10日成立，註冊資本為人民幣1,000萬元。

本公司之附屬公司，即永嘉康寧醫院有限公司（永嘉康寧醫院有限公司），於2012年12月12日成立，註冊資本為人民幣1,000萬元。

本公司之附屬公司，即樂清康寧醫院有限公司（樂清康寧醫院有限公司），於2013年3月3日成立，註冊資本為人民幣1,000萬元。

本公司之附屬公司，即樂清怡寧中西醫結合醫院有限公司（樂清怡寧中西醫結合醫院有限公司），於2006年4月4日成立，註冊資本為人民幣1,000萬元。本公司之附屬公司，即樂清邦爾中西醫結合醫院有限公司（樂清邦爾中西醫結合醫院有限公司），於2013年3月3日成立，註冊資本為人民幣1,000萬元。

%

本公司之附屬公司

溫州康寧醫院股份有限公司